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ABSTRACT 
 
Xanthones or xanthen-9-ones (dibenzo-γ-pirone) comprise an important class of 
oxygenated heterocycles whose role is well-known in Medicinal Chemistry. The biological 
activities of this class of compounds are associated with their tricyclic scaffold but vary depending 
on the nature and/or position of the different substituents. To obtain more structural diversity 
and quantities for biological assays, suitable and efficient synthetic processes are necessary. 
Different synthetic methodologies, “classical” and “non-classical”, namely microwave 
assisted organic synthesis, heterogeneous catalysis and a combination of heterogeneous catalysis 
with microwave irradiation, were applied to obtain new xanthone derivatives. 
 
Thus, this thesis reports the synthesis and structure elucidation of seven new compounds: 
1,3-dihydroxy-5-methoxyxanthone (X1), 1-hydroxy-3-mesyloxy-5-methoxyxanthone (X2),   1-
hydroxy-5-methoxy-3-(3-methylbut-2-enyloxy)xanthone (P1), 1-hydroxy-5-methoxy-4-(3-
methylbut-2-enyl)-3-(3-methylbut-2-enyloxy)xanthone (P2), 1-hydroxy-5-methoxy-4-(3-
methylbut-2-enyl)-6’,6’-dimethyl-4’,5’-dihydropyran(2’,3’:3,2) xanthone (P3), 1-hydroxy-5-
methoxy-6’,6’-dimethyl-4’,5’-dihydropyran(2’,3’:3,2)xanthone (P4) and 1-hydroxy-5-methoxy-
6’,6’-dimethyl-4’,5’-dihydropyran(2’,3’:3,4)xanthone (P5), as well as the evaluation of their 
antitumor activity. 
The synthesized xanthones and respective derivatives with prenyl units were structurally 
elucidated by spectroscopic methods including IR, NMR (1H, 13C, HSQC and HMBC) and HRMS. 
Their biological activity was evaluated by a screening assay for inhibition of growth of human 
tumor cell lines.  
 
 
Keywords: Prenylated xanthones, synthesis, microwave assisted organic synthesis (MAOS), 
heterogeneous catalysis, growth inhibitory activity of tumor cell lines. 
  
iv 
 
RESUMO 
 
As xantonas ou xanten-9-onas (dibenzo-γ-pirona) constituem uma importante classe de 
heterociclos oxigenados com um papel bem conhecido na Química Medicinal. As atividades 
biológicas desta classe de compostos estão relacionadas com o seu esqueleto tricíclico e variam 
consoante a natureza e/ou posição dos diferentes substituintes. De forma a obter maior 
diversidade estrutural e quantidades para ensaios biológicos, são necessários processos sintéticos 
adequados e eficientes. 
 
 Diferentes metodologias sintéticas, “clássicas” e “não-clássicas”, nomeadamente síntese 
orgânica assistida por micro-ondas, catálise heterogénea e a combinação de catálise heterogénea 
com radiação micro-ondas, foram aplicadas para obter novos derivados xantónicos. 
Assim, esta tese descreve a síntese e elucidação estrutural de sete novos compostos: 1,3-
di-hidroxi-5-metoxixantona (X1), 1-hidroxi-3-mesiloxi-5-metoxixantona (X2), 1-hidroxi-5-metoxi-3-
(3-metilbut-2-eniloxi)xantona (P1), 1-hidroxi-5-metoxi-4-(3-metilbut-2-enil)-3-(3-metilbut-2-
eniloxi)xantona (P2),  1-hidroxi-5-metoxi-4-(3-metilbut-2-enil)-6’,6’-dimetil-4’,5’di-hidropirano(2’,3’:3,2) 
xantona (P3), 1-hidroxi-5metoxi-6’,6’-dimetil-4’,5’-di-hidropirano(2’,3’:3,2)xantona (P4) e 1-hidroxi-5-
metoxi-6’,6’-dimetil-4’,5’-di-hidropirano(2’,3’:3,4)xantona (P5), assim como a avaliação da sua atividade 
antitumoral. 
As xantonas e os respetivos derivados prenilados sintetizados foram caraterizados 
estruturalmente por métodos espetroscópicos, nomeadamente IV, RMN (1H, 13C, HSQC e HMBC) e 
EM de alta resolução. A sua atividade biológica foi avaliada através de um screening para a 
inibição de crescimento de linhas celulares tumorais humanas.  
 
 
Palavras-chave: Xantonas preniladas, síntese, síntese assistida por micro-ondas, catálise 
heterogénea, atividade inibidora do crescimento de linhas celulares tumorais. 
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ABBREVIATIONS AND SYMBOLS 
 
AChE Acetylcholinesterase 
A375-C5 Malignant melanoma cell line 
13C NMR Carbon nuclear magnetic resonance 
1H NMR  Proton nuclear magnetic resonance 
CEQUIMED-UP Centro de Química Medicinal – Universidade do Porto 
d  Doublet 
DCX Dicamphanoyl-dihydropyranoxanthone 
dd  Double doublet 
DMSO  Dimethyl sulfoxide 
DMXAA 5,6-dimethylxanthenone-4-acetic acid 
GI50   Concentration of compound that causes 50% inhibition of the growth of 
tumor cell lines 
HIV Human immunodeficiency virus 
HMBC Heteronuclear Multiple Bond Correlation 
HRMS High Resolution Mass Spectrometry 
HSQC Heteronuclear Single Quantum Correlation 
IBX 2-Iodoxybenzoic acid 
IR  Infrared spectroscopy 
IUPAC  International Union of Pure and Applied Chemistry 
J  Coupling constant 
LDL Low density lipoprotein 
m  Multiplet 
MAO Monoamine oxidase 
MAOS Microwave assisted organic synthesis 
MCF-7 Breast adenocarcinoma cell line 
mp  Melting point 
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MRSA Methicillin-resistant Staphylococcus aureus 
MW  Microwave 
NCI National Cancer Institute 
NCI-H460 Non-small cell lung cancer cell line 
NMR Nuclear magnetic resonance 
N,N-DMA               N,N-dimethylaniline 
NO Nitric oxide 
NSCLC Non-small cell lung cancer 
PAF Platelet activating factorP-gp P-glycoprotein 
q Quadruplet 
s  Singlet 
SRB Sulforhodamine B 
SNAr  Aromatic nucleophilic substitution 
t  Triplet 
tan δ Loss tangent 
THF Tetrahydrofuran 
TLC  Thin layer chromatography 
VEGF Vascular endothelial growth factor 
VRE Vancomycin-resistant enterococci 
WHO World Health Organization 
  
vii 
 
OUTLINE OF THE THESIS 
 
The present thesis consists of five chapters: 
 
I. INTRODUCTION  
The state-of-the-art concerning the major classes of xanthone derivatives – prenylated and 
caged xanthones are presented. The biological activities of xanthones, namely antitumor are 
highlighted. The synthesis through “classical” and “non-classical” methodologies like MAOS and 
heterogeneous catalysis are described. 
 
II. AIMS 
Herein the main objectives of the present thesis are described.  
 
III. RESULTS AND DISCUSSION 
This section is divided in three parts: synthesis, structural elucidation and biological assays of 
the obtained compounds, concerning inhibitory activity of growth of human tumor cell lines. 
 
IV. EXPERIMENTAL PART 
In this chapter, the experimental procedures for the synthesis, structure characterization and 
biological evaluation of the synthesized compounds are detailed. 
 
V. CONCLUSIONS 
This chapter includes the general conclusions of the developed work. 
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INTRODUCTION 
  
Throughout the ages, Nature has catered to the basic needs of humans, not the least of 
which is the provision of medicines for the treatment of a wide spectrum of diseases. Plants, in 
particular, have given a significant contribution to the development of therapeutic systems. The 
continuing and essential role played by plant-based systems in the healthcare of many different 
cultures has been extensively documented and the World Health Organization (WHO) has 
estimated that in some Asian and African countries, 80% of the population depend on traditional 
medicine for primary health care (Cragg, G.M. et al., 2009; http://www.who.int/en/). 
Besides directly isolated natural products can be the actual drugs used for the treatment 
of a given disease, these natural molecules can serve as lead compounds for the development of 
analogues, with optimized pharmacological properties. They have been evolutionarily selected to 
bind to biological macromolecules representing some of them “privileged structures”, which are 
excellent templates for the synthesis of novel, biologically active, natural product-like molecules. 
Some problems concerning natural products are the lack of druglike properties, namely 
associated with pharmacokinetic properties and/or toxicity, so they need to be fine-tuned to 
possess the properties desired in a clinically useful drug. Optimization frequently entails 
modification, removal, or introduction of functional groups and stereocenters or more drastic 
remodelling of the basic scaffold to improve physicochemical and pharmacokinetic properties. 
Also the structural diversity is limited by the available biosynthetic pathways of the host organism, 
but the power of synthetic chemistry can be harnessed to access a greater extent of possible 
modifications and structural diversity (Cragg, G.M. et al.,2009; Kinghorn, A.D. et al., 2011). 
 
Xanthones are one of the main compounds of the exotic fruit of Garcinia Mangostana L., 
mangosteen, which have showed to posses diverse health benefits. In Southeast Asia, this fruit 
has been appreciated for centuries and strongly used as folk medicine due to their bioactive 
compounds. These allowed the scientists to notice its potential as a source of new therapeutic 
agents (Adnan, N. and Othman, N., 2012; Saslis-Lagoudakis, C.H. et al., 2011; Wittenauer, J. et al., 
2012).  
As in CEQUIMED-UP the synthesis of xanthone derivatives and their investigation as 
potential antitumor agents has been a research area in increasing development (Palmeira, A. et 
al., 2010; Pinto, M. and Castanheiro, R., 2009a and 2009b), this class of compounds was chosen to 
be studied in this thesis. 
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1. XANTHONES 
 
Xanthones or xanthen-9-ones are heterocyclic compounds with the dibenzo-γ-pyrone 
scaffold (Pinto, M. and Castanheiro, R., 2009a and 2009b; Sousa, M.E. and Pinto, M., 2005) (Figure 
1). Xanthone derivatives are secondary metabolites produced by plants and microorganisms that 
have a structural relationship with other γ-pyrone moieties: flavonoids (2) and chromones (3) 
(Figure 2). The xanthones from higher plants appear to be associated mainly with the families 
Clusiaceae and Gentianaceae (Nualkaew, N. et al., 2012; Pinto, M. and Castanheiro, R., 2009a and 
2009b; Vieira, L. and Kijjoa, A., 2005). Because of their diverse pharmacological properties, 
xanthone derivatives have an important and well-known role in Medicinal Chemist. 
 
 
Figure 1. Xanthonic scaffold and numbering (according to IUPAC, 
http://www.iupac.org;http://www.chem.qmul.ac.uk/iupac/)  
 
 
 
 
Figure 2. Scaffolds containing a γ-pyrone moiety (present in bioactive secondary metabolites) 
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Concerning the biosynthetic metabolic route in higher plants, xanthones are generated 
through two pathways: acetate (Figure 1 - ring A, numbered from 1 to 4) and shikimate (Figure 1 - 
ring B, numbered from 5 to 8). 
Xanthones can present different substituents on their scaffold, allowing great structural 
diversity (Na, Y., 2009; Sousa, M.E. and Pinto, M., 2005). According to this, xanthones can be 
classified into the major groups: simple oxygenated xanthones, xanthones glycosides, prenylated 
and related xanthones, xanthonic dymers, caged xanthones, xanthonolignoids and miscellaneous 
xanthones. The simple oxygenated xanthones can further be subdivided into sub-groups 
according to the degree of oxygenation in mono-, di-, tri-, tetra-, penta- and hexaoxygenated 
xanthones (Fotie, J. and Bohle, D.S., 2006). 
 
Although natural products have always played an important role in drug discovery, 
providing bioactive compounds of great interest in Medicinal Chemistry (Kinghorn, A.D. et al., 
2011), xanthones from natural origin are relatively limited in type and position of the substituents 
imposed by the biosynthetic pathways (Sousa, M.E. and Pinto, M., 2005). Due to their interesting 
structural scaffold and vast pharmacological properties, a lot of compounds was isolated from 
natural resources and/or many new xanthone-natural mimics were synthesized as novel drug 
candidates (Jun, K.Y. et al., 2011). Therefore, natural products can also be an important source of 
novel molecular architecture.  
The biological activities of this class of compounds are associated with their tricyclic 
scaffold but vary depending on the nature and/or position of the different substituents. The 
bioactivities of natural and synthetic analogues have been extensively reported and reviewed in 
the literature (El-Seedi, H.R. et al., 2010; Pinto, M. and Castanheiro, R., 2009a and 2009b; Pinto, 
M. et al., 2005). In this thesis, diverse activities will be discussed later, particularly antitumor (Giri, 
R. et al., 2010; Jun, K.Y. et al., 2011; Krajarng, A. et al., 2012; Na, Y., 2009; Woo, S. et al., 2007). 
  
 The major group of naturally occurring xanthones are prenylated xanthones, a group that 
have very important and diverse pharmacological activities. As a consequence of this, using the 
prenylated xanthone α-mangostin as a model, synthetic strategies leading to new prenylated 
derivatives have been explored. 
 
  
5 
 
1.1. PRENYLATED XANTHONES 
 
Prenylated xanthones are characterized by the presence of a prenyl group (C5 unit) in the 
xanthonic scaffold and represent the major group of naturally occurring xanthones (Pinto, M. and 
Castanheiro, R., 2009a and 2009b). The study of xanthone derivatives with important bioactivities 
has shown a relationship between biological activity and the presence of prenyl groups in key-
positions on the xanthone nucleus. Therefore, this feature becomes an important structural point 
for the interaction of xanthones with some targets, allowing an increase of selectivity and 
potency. 
 Although the C-prenyl derivatives are much more represented in Nature, oxyprenylated 
compounds are also found, and among them, only a small number are both C and O-prenylated. 
The main substituents (C5 group) found in prenylated xanthones included the common 3-
methylbut-2-enyl or isoprenyl group (A), the less frequent 2-hydroxy-3-methylbut-3-enyl group 
(B) and also the 1,1-dimethylprop-2-enyl or 1,1-dimethylallyl group (C). Compounds containing 
the 2,2-dimethyldihydropyran (D), the 2,2-dimethylpyran (E) and the 2,3,3-trimethyldihydrofuran 
(F) groups, which are the result of cyclization of the substituents A and C respectively, with the 
ortho hydroxyl group, could also be found (Figure 3). Modifications of these side chains by 
hydroxylation, hydrogenation, cyclization, and Claisen rearrangement reactions can also occur 
(Pinto, M. and Castanheiro, R., 2009a). 
 
 
 
Figure 3. Main substituents found in prenylated xanthones (Pinto, M., Castanheiro, R., 2009a) 
 
The prenyl substituents can occur in any position of the xanthonic scaffold, but there are 
some preferential positions. For example, substituents A and C usually appear in C2, C4 and C8, 
6 
 
while cyclic substituents like D and E frequently appear in C2-C3, C3-C4  (and C5-C6, C7-C8  for D) of 
the xanthonic scaffold (Pinto, M. and Castanheiro, R., 2009a). 
The biological activities of prenylated xanthones are vast, standing out the antitumor 
activity. Pinto and Castanheiro carefully review the activities of these xanthones and highlighted 
their importance as chemopreventive agents against chemical induced carcinogenesis and also as 
antitumor agents (Pinto, M. and Castanheiro, R., 2009b). In Obolskiy study (Obolskiy, D. et al., 
2009), several xanthone derivatives, extracted from the steam and root bark of mangosteen, 
particularly α-mangostin, β-mangostin and γ-mangostin (Figure 4), showed strong antitumor and 
antioxidant activity. These and other studies suggest that prenylated xanthones could be useful as 
chemotherapeutic agents for the treatment of certain cancers (Castanheiro, R. et al., 2009a; Giri, 
R. et al., 2010; Jun, K.Y. et al., 2011; Krajarng, A. et al., 2012; Na, Y., 2009; Woo, S. et al., 2007). It 
is important to note that prenylated xanthones exhibit a wide range of other activities in addition 
to this one, as will be discussed later in this thesis. 
 
            
                                        
 
 
 
 
Figure 4. α-mangostin (A), β-mangostin (B) and γ-mangostin (C) 
 
 
                  A                                                                            B    
       C     
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1.2. CAGED XANTHONES 
 
Caged xanthones are a group of polyprenylated xanthones mainly extracted from the 
Garcinia genus (Guttiferae family). They are characterized by a unique 4-oxa-tricyclo[4.3.1.0]dec-
2-one scaffold, in which a highly substituted tetrahydrofuran core with three quaternary carbon 
centers is featured (Figure 5). 
Most of the Garcinia genus contain prenylated xanthones, but caged xanthones mainly 
occur in five species: G. morella, G. hanburyi, G.bracteata, G. gaudichaudii, and G. scortechinii, 
widely distributed in Southeast Asia. From the biosynthetic point of view, caged xanthones are 
thought to be derived from a common benzophenone intermediate of a mixed shikimate-acetate 
pathway that has undergone plant-specific prenylations, rearrangements, and/or oxidation 
reactions (Han, Q-B. and Xu, H-X, 2009). 
As suggested by structure-activity relationship studies, the caged core is responsible for 
the bioactivities of this class of compounds. Among other activities like anti-viral, antibacterial and 
neurotrophic, they have been reported to have potent antitumor activity, with gambogic acid 
being the more notorious (Reutrakul, V. et al., 2007; Yen, C. et al., 2012). 
With an unusual caged skeleton and notable bioactivity, this promising class of xanthones 
attracts increasing attention among scientist from diverse areas. 
 
                                     
Isomorellinol                                                     30-Hydroxygambogic acid 
O
OH
O
O
O
HOOC
H
H
O
                              
Morellic acid                                                              Gambogic acid 
Figure 5. Examples of caged xanthones with antitumor activity 
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2. ACTIVITY OF XANTHONES 
 
Xanthone scaffold is considered a “privileged structure” since this class of compounds can 
interact with diverse drug targets and exhibit multiple pharmacological effects. In the field of 
Medicinal Chemistry, groups of compounds that can bind to different classes of receptors have 
attracted much attention as potential drug candidates (Kappe, C.O. and Dallinger, D., 2005; Vieira, 
L. and Kijjoa, A., 2005). 
Many naturally occurring xanthones and their prenylated derivatives are found to exhibit 
significant biological and pharmacological properties, such as antibacterial, antifungal and 
antitumor activities (El-Seedi, H.R. et al., 2010) and it can be inferred that the presence of prenyl 
groups can be associated with an improvement of potency and selectivity for some of these 
properties. Therefore, there is interest in obtaining this type of compounds to evaluate their 
antitumor activity. For this purpose, in this thesis, molecular modifications of the 1,3-dihydroxy-5-
methoxyxanthone (X1) were carried out to obtain xanthone derivatives with prenyl substituents, 
either in a cyclic or as an open-chain form (Castanheiro, R. et al., 2009b). 
Once xanthones posses a wide range of biological properties, it will be described the main 
activities reported in the last ten years (Figure 6), with special emphasis on antitumor activity. 
 
 
 
 
 
Figure 6. Some pharmacological activities of xanthones (El-Seedi, H.R. et al., 2010) 
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• Insecticidal and Antihelmintic Activities 
 
Although the significant number of helminth infections, few anthelminthic drugs are 
available for human use. The activities of α-mangostin (Figure 7), a major bioactive xanthone 
isolated from Garcinia mangostana and of the synthetic derivative mangostin diacetate were 
tested by Keiser, J.  α-Mangostin has showed promising activities against the trematodes 
Schistosoma mansoni, Echinostoma caproni, and Fasciola hepatica in vitro, but not in vivo (Keiser, 
J. et al., 2012). 
Xanthonol (Figure 7) has been shown to have moderate insecticidal and antihelmintic 
activities, being considered a promising lead for safe, efficacious systemic antiparasitic drugs, with 
new modes of action. This result is very important because an effective treatment for human and 
animal infections is urgently needed, since the efficacy of current insecticides and anthelmintics is 
limited by low therapeutic indices, environmental hazards and development of resistance. 
(Ondeyka, J.G. et al., 2006). 
         
                    Xanthonol                                                                          α-Mangostin 
 
Figure 7. Xanthonol and α-mangostin structures 
 
 
 
• Antimicrobial Activity 
 
Bacterial and fungal resistance to antibiotics has become a serious problem in the 
treatment of infectious diseases. The discovery of new antimicrobial agents is very important 
because of the increased incidence of infections by opportunistic fungi, especially in patients 
whose immune system has been compromised by AIDS, cancer, diabetes, age or other causes. 
Several studies have shown that diverse xanthones (α-, β-, γ-mangostin, among others) exhibit 
moderate to high inhibitory activities against diverse human pathogenic microorganisms, 
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particularly multi drug-resistant organisms such as the methicillin-resistant Staphylococcus aureus 
(MRSA) and vancomycin-resistant enterococci (VRE). These compounds warrant further attention 
as possible antibiotics with activities against various human pathogenic microorganisms (El-Seedi, 
H.R. et al., 2010). 
 
 
 
• Antiprotozoal Activity 
 
Protozoa such as trypanosomes, leishmania and the malaria parasites (Plasmodium spp.) 
are responsable for serious diseases. Malaria remains the most important parasitic disease, 
causing 2–3 million deaths every year, and the emergence and rapid spread of chloroquine-
resistant strains of Plasmodium falciparum threaten to increase the annual death toll (Azebaze, 
A.G.B. et al., 2007). Being in the past considered a disease of underdeveloped countries, today, 
due to climate changes, it is estimated that it can reach developed countries like United States, 
and therefore the attention and the investment applied in the discovery of new therapeutic drugs 
against malaria are increasing. Xanthones have already been evaluated by their antimalarial 
activity and had proven to be potential antimalarial agents (Dua, V.K. et al., 2004; Portela, C. et 
al., 2007). 
Prenylated xanthones from Garcinia subelliptica have shown trypanocidal activity against 
Trypanosoma cruzi, the etiologic agent for Chagas’ disease (Abe, F. et al., 2003). 
 
 
 
• Antiviral and Anti-HIV-1 Activities 
 
Xanthones are being evaluated by their neuraminidase inhibitory activity (Ryu, H.W. et al., 
2010). The neuraminidase family is a group of exo-acting enzymes that are important in a varied 
array of cell–cell interactions and cell–molecule recognition processes. Neuraminidase has a well 
known role in infectivity of the influenza virus and recent studies have also shown that it can 
enable several bacterial pathogens to evade the host immune system. Thus development of 
inhibitors of neuraminidase may provide a new weapon for the treatment of several pathogenic 
diseases.  
Concerning to anti-HIV activity, mangiferin (Figure 8) showed good activities, being now a 
novel anti-HIV agent effective against resistant HIV-strains (Wang, R.R. et al., 2011a). Gambogic 
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acid (Figure 5) have also shown moderate HIV-1 inhibitory activities in the reverse transcriptase 
assay (Reutrakul, V. et al., 2007). More recently, dicamphanoyl-dihydropyranoxanthone (DCX-
Figure 8) derivatives, previously discovered as novel anti-HIV agent, were evaluated for their 
potential to reverse multi-drug resistance in a cancer cell line over-expressing P-glycoprotein (P-
gp). DCX can act as dual inhibitor of HIV replication and chemoresistance mediated by P-gp. As 
such, they may be useful in combination therapy to overcome P-gp-associated drug resistance for 
AIDS treatment (Zhou, T. et al., 2012a and 2012b).  
 
                  
DCX                                                                    Mangiferin 
 
 
 
Figure 8. DCX and Mangiferin structures 
 
 
 
• Antioxidant Activity 
 
Xanthones with phenolic groups have been described for their remarkable antioxidant 
activities, namely scavenging ones (Chin, Y-W. et al., 2008; Mahabusarakam, W. et al., 2006; Rana, 
V.S. and Rawat, M.S.M., 2005). Beside free radical scavengers, they can act as metal chelators as 
well as inhibitors of lipid peroxidation. These properties have been implicated with their 
hepatoprotective, anti-inflammatory and cancer chemopreventive actions (Pinto, M. et al., 2005). 
One example of xanthone with this activity is the mangiferin (Figure 8), a “super 
antioxidant” more potent than vitamin C and E (Wu, Z. et al., 2010). 
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• Cardioprotective effect and cardiovascular activity 
 
Many xanthones with catechol systems are considered anti-atherosclerotic since they 
have anti-low density lipoprotein (LDL) oxidation and acyl CoA:cholesterol acyltransferase (ACAT) 
inhibition activities, both of which are potentially useful for treating and/or preventing 
atherosclerosis and hypercholesterolemia (Park, K.H. et al., 2006). They showed to have potential 
as cardiovascular protective agents (Jiang, D.J. et al., 2004; Marona, H. et al., 2009; Wang, Y. et al., 
2008). 
Xanthones can be useful in several pathologies like asthma, allergies, inflammation and 
thrombosis, once they are PAF-antagonists. PAF – exogenous platelet activating factor, initiates 
anaphylactic hypotension being an important mediator of those pathologies. Xanthones isolated 
from various plants showed inhibitory effects on PAF-induced hypotension, some of them with an 
activity higher than that of gingkolide-B, a recognized natural PAF-antagonist from Gingko biloba 
(Oku, H., et al., 2005). 
 
 
 
 
• Anti-allergic and Anti-inflammatory Activity 
 
Mast cells are known to participate in allergic and anaphylactic reactions related to 
immune responses. Various stimuli can activate mast cells, causing the release a number of 
biologically active molecules like histamine, serotonin, Interleukin-6 (IL-6), leukotriene C4 (LTC4), 
and prostaglandin D2 (PGD2), leading to allergic and inflammatory diseases, especially skin 
inflammation and allergic asthma. The diprenylated xanthones isolated from Garcinia 
Mangostana α-and γ-mangostin were investigated for their inhibitory effect on the allergy 
mechanism (Chae, H., et al., 2012). α-and γ-mangostin were found to modulate the production of 
IL-6, LTC4, PGD2 and the release of histamine, and also repress cyclooxygenase-2 expression, 
suggesting that α-and γ-mangostin may be useful as anti-allergic and anti-inflammatory molecules 
in preventing or treating various diseases (Nakatani, K. et al., 2002). 
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• Neuropharmacological Activity 
 
Alzheimer’s disease is the most common age-related degenerative brain disorder, which 
causes gradual, irreversible losses of memory and other mental abilities. Once it is associated with 
low brain neurotransmitters levels, it is fundamental to find new cholinesterase inhibitors as new 
drug candidates to treat Alzheimer’s disease and related dementias. Most currently known 
natural inhibitors of acetylcholinesterase (AChE) are alkaloids, which have the disadvantages of 
short half-lives and undesirable side effects (Lopez, S. et al., 2002). Thus, xanthones can play an 
important role as non-alkaloid cholinesterase inhibitors, exhibiting potent inhibitory activities 
against AChE (Urban, A. et al., 2004). Since multiple pathogenic factors, including aggregated 
amyloid-β peptide and tau protein, excessive levels of transition metals, oxidative stress and 
reduced acetylcholine levels, are implicated in Alzheimer’s disease, multipotent agents with 
diverse targets are expected to be more effective for treating Alzheimer’s disease than single-
target counterparts (Mattson, M.P., 2004). Once xanthone are “privileged structures” that can act 
in different receptors, multiple pharmacological effects can be combined into one xanthone 
molecule.  
In this way, is also important to note that xanthones are also capable to inhibit 
monoamine oxidase (MAO), an enzyme that exists as two isoenzymes – MAO-A and MAO-B, with 
an important role in the metabolism of neurotransmitters, including serotonin and dopamine 
(Harkcom, W.T. and Bevan, D.R., 2007; Nunez, M.B. et al., 2004; Ohishi, N, et al., 2000; Thull, U., 
et al., 1993). It was proved that the dysfunction of this enzyme is associated with neurological 
disorders like depression, drugs abuse and attention deficit, revealing the importance of finding 
new and effective MAO-inhibitors and therefore the importance of the xanthones (El-Seedi et al., 
2010). 
Xanthones are multipotent agents, found to be efficient radical scavengers, MAO 
(isoenzymes A and B) inhibitors and potential AChE inhibitors (El-Seedi et al., 2010; Mattson, M.P., 
2004), thereby fundamental tools in the treatment of dementias. 
 
 
 
• α-Glucosidase Inhibitory Activity 
 
Nowadays, several diseases like obesity, heart disease and diabetes are rising. In the case 
of diabetes, glycosidases, a large family of enzymes that are involved in the processing of complex 
carbohydrates have been consider as an important therapeutic target. α-Glucosidase inhibitors 
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also show promising therapeutic potential in the treatment of disorders such as human 
immunodeficiency virus (HIV), as referred above, metastatic cancer, and lysosomal storage 
diseases (Melo, E.B. et al., 2006). In the specific case of diabetes mellitus type II (Floris, A.L. et al., 
2005), α-glucosidase is a key enzyme required for cleavage of maltose for absorption of glucose 
into blood in the small intestine. Thus, abnormally high levels of plasma glucose after a 
carbohydrate meal may be regulated by α -glucosidase inhibitors. 
Xanthones are now being study as α-glucosidase inhibitors because of the high level of 
natural abundance and antioxidant potential (Ryu, H.W., et al., 2011). They proved to have 
antihyperglycemic activity, helping to low postprandial glucose absorption by retarding the 
cleavage of complex carbohydrates (Seo, E.J. et al., 2007). One good example of this inhibitory 
activity is γ-mangostin (Ryu, H.W., et al., 2011). 
 
 
 
• Cytotoxicity and Cancer Chemoprevention Activities 
 
Despite the advances in anticancer drug development, cancer is still a major cause of 
human mortality and morbidity. Today there are powerful tools for the development of new 
cancer treatments, but small molecules like xanthones possessing potent anticancer activities are 
still attractive as novel anticancer drug candidates (Woo, S. et al., 2010). 
Among a myriad of biological activities described for xanthones, the in vitro growth 
inhibitory activity on tumor cell lines appeared to be quite significant, since they exert their effect 
on a wide range of different tumor cell lines. Apart from the antitumor effect, some extracts 
containing xanthones have been described for their antimutagenic properties and for their cancer 
chemopreventive effect, acting as inhibitors of tumoral promoters. The xanthones reported to 
date as antitumor agents include the xanthone molecule itself (Figure 1), as well as other natural 
and synthetic derivatives (Palmeira, A. et al., 2010; Pinto, M. et al., 2005). 
 
Mangosteen, Garcinia mangostana, is a fruit found in South East Asia that has been used 
as traditional medicine. Its therapeutic properties are related with xanthones, its principal 
secondary metabolites (Peres, V. et al., 2000). Prenylated xanthones isolated from young fruits of 
Garcinia mangostana, namely α, β, and γ-mangostin (Figure 4) showed cytotoxic activity against 
several human tumor cell lines (El-Seedi, H.R. et al., 2010; Suksamrarn, S. et al., 2006). α-
Mangostin (Figure 7), one of major xanthones isolated from mangosteen, has been reported for 
its antiproliferative, antitumor growth, metastasis suppression and apoptotic effects against 
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human breast cancer, prostate cancer , colon cancer and leukaemia (Han, A.-R. et al., 2009; Lee, 
Y.-B. et al., 2010; Na, Y., 2009; Woo, S. et al., 2007). 
 
Another impressive natural xanthone is psorospermin (Figure 9), a dihydrofuranxanthone 
of the African plant Psorospermum febrifugum. This molecule showed excellent anticancer activity 
against human and murine cancer cell lines (Na, Y., 2009). Psorospermin advanced to clinical trials 
but further development for the commercial market suffered from limited resources. Meanwhile 
stereoselective total synthesis for psorospermin was reported (Schwaebe, M.K., et al., 2005), 
giving a future opportunity to clinical trials with this compound. Psorospermin has shown 
biological activities via intercalation of the xanthone group with DNA base pairs (Shen, R. et al., 
2010) and alkylation of epoxide by N7-guanine in the presence of topoisomerase II (Na, Y., 2009; 
Woo, S. et al., 2007). 
Topoisomerases are critical cellular enzymes necessary for cell proliferation, being 
involved in the DNA replication. Because of the importance of these enzymes in the cell 
proliferative process, topoisomerases are one of the major targets in anti-cancer drug 
development. Also, compounds that can act as DNA cross-linking agents, inhibiting replication and 
transcription and therefore causing cell death, are an important class of anti-tumor drugs 
targeting DNA. In Sangwook Woo study, these two mechanisms were tested and the synthesized 
xanthones exhibited strong inhibitory activity against different cancer cell lines (Woo, S. et al., 
2010). 
 
Also among these interesting xanthones is the polyprenylated xanthone gambogic acid 
(Figure 5), the most abundant caged Garcinia xanthones, isolated from the resin of the Garcinia 
hurbury tree. In finished phase II clinical trials in China, this compound was identified as a potent 
anticancer agent during highthroughput screening to determine if this agent could be used as a 
novel anticancer agent. A variety of mechanisms have been proposed by which gambogic acid 
inhibits the proliferation of cancer cells and induces apoptosis. These include inhibition of 
antiapoptotic proteins, induction of apoptosis-associated proteins, inhibition of topoisomerase II, 
among others. Other reported pathway is the inhibition of angiogenesis by suppressing vascular 
endothelial growth factor (VEGF) signalling, a factor that is highly expressed in human cancer 
tissues. It was also found that the apoptotic effect of gambogic acid was not related to cell cycle 
arrest, a common pathway for many current natural anticancer drugs, including paclitaxel and 
that gambogic acid reversed docetaxel resistance in gastric cancer cells, further supporting the 
potential of gambogic acid as a prospective anticancer drug candidate (Sun, H. et al., 2012; Wang, 
X. et al., 2011b). 
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One the best-known synthetic xanthone candidate as anticancer drug is 5,6-
dimethylxanthenone-4-acetic acid (DMXAA), also known as Vadimezan (Figure 9). Once 
angiosenesis is a fundamental process in tumor growth and progression, considerable efforts have 
been directed to antiangiogenic therapy as a new treatment for human cancers. DMXAA, a simple 
carboxylated xanthone, was discovered in a structure-activity relationship study involving a series 
of xanthone-4-acetic acids related to the parent drug flavone acetic acid. DMXAA was the most 
effective analog and was then selected for detailed evaluation (Palmeira, A. et al., 2010). 
DMXAA is a vascular disrupting agent that leads to the collapse of tumor vasculature and 
subsequent tumor cell death (Na, Y., 2009) by immunomodulation and cytokines induction. It also 
possesses inductive effects in 5-hydroxytryptamine and nitric oxide (NO). In this way, DMXAA may 
be applied in synergy not only with conventional cytotoxic agents and other antivascular agents, 
but also with immunomodulatory agents that increase host-mediated responses such as cytokines 
and NO (Pinto, M. et al., 2005). This compound has attracted scientific interest because of its 
excellent pharmacological profile since its discovery. Its multiple actions can be used as a basis to 
improve antivascular therapy. 
Until recently, DMXAA was the most advanced in clinical development among 
investigational vascular disrupting agents, being tested mainly for lung cancer. However, two 
phase III trials of this small molecule in the first- and second-line settings in non-small cell lung 
cancer (NSCLC) were terminated early after the observation of no overall survival benefit 
(Reckamp, K.L., 2012; Rogosin, S. and Sandler, A.B., 2012).  
 
 
                               
 
                          Psorospermin                                                             DMXAA 
                
      
 
Figure 9. Psorospermin and DMXAA structures 
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Once xanthones can exhibit their antitumor activity through different mechanisms of 
action, in table 1 are summarized xanthone derivatives/substituents and their mechanisms. 
 
Table 1. Mechanisms of action for xanthone derivates with antitumor activity (Pinto, M. et al., 2005 
and references cited therein)  
 
 MECHANISMS 
 
XANTHONE DERIVATIVES/SUBSTITUENTS 
Apoptosis via caspase 3 Prenyl; Glycosyl; Methylenecarboxy 
Aromatase inhibition Imidazolyl; Triazolyl 
DNA binding Pyrano; Amino; Oxygenated 
DNA breaks and DNA-proteins cross-links Furano; Epoxy 
DNA synthesis suppression Epoxy; Polycyclic; Prenyl; Dialkylamine; 
Oxygenated; Furano 
11-β-Hydroxylase inhibition Xanthone-anthraquinone 
17-α-Hydroxylase/C17,20-lyase inhibition Imidazolyl; Triazolyl 
Immunomodulation, cytokines induction Methylenecarboxyl 
Kinases modulation Dihydroxy; Dihydroxy/nitro; 
Methylenecarboxy; Prenyl; Glycosyl; Formyl; 
Hydroxyl; Xanthonolignoids; Oxygenated 
Phospholipase C inhibition Xanthone-chromone, Tetra-oxygenated 
Prostaglandin (PG) E2 receptors blocking Prenyl; Carboxy 
Protein synthesis suppression and RNA 
synthesis suppression 
Epoxy 
Sphingomyelinases inhibition Prenyl 
Topoisomerases I and II inhibition Furano; Prenyl; Oxygenated; Pyrano; 
Xanthonolignoids; Carboxamide; Epoxy; Acyl; 
Thioxanthones 
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Transforming growth factor-β (TGF-β) gene 
expression increasing 
Glycosyl 
Vasculogenic mimicry inhibition Methylenecarboxyl 
 
 
With all these biological activities and their promising value is easily understandable that 
xanthones, either from synthesis or natural resources, are considered a class of compounds with 
great interest. 
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3. SYNTHESIS OF XANTHONES 
 
Once the biosynthetic routes are a limiting factor for the structural variation of naturally-
occurring xanthones, the chemical synthesis can be a good alternative to create new derivatives 
as well as to rationalize the structure-activity relationship. 
 
One of the first synthesis of xanthones was made by Michael and Kostanecki, involving the 
distillation of a mixture of a phenol, an o-hydroxybenzoic acid and acetic anhydride (Sousa, M.E. 
and Pinto, M., 2005). Since then, different methods have been developed, with higher yields and 
less drastic experimental conditions (Sousa, M.E. and Pinto, M., 2005). 
Three classical methods can be used to synthesize xanthones: 
• the Grover, Shah, and Shah (GSS) reaction; 
• the synthesis via benzophenone; 
• the synthesis via diaryl ethers intermediates. 
 
The GSS reaction (Figure 10) is a one-pot process for preparing hydroxyxanthones and still 
popular due to usually accessible materials. The xanthone is obtained by adding a salicylic acid 
derivative (1) and a suitable phenol (2), both heated together with zinc chloride in phosphoryl 
chloride as solvent. It can afford the xanthone skeleton (4), directly only if the benzophenone 
intermediate (3) carries another hydroxyl group at 6 or 6’ position, which means if an alternative 
site for cyclization is available (*). 
 
 
Figure 10. Synthesis of xanthones via GSS reaction 
 
The xanthone synthesis via benzophenone intermediate (Figure 11, I) begins with 
condensation, by Friedel-Crafts acylation, of a substituted benzoyl chloride with a phenolic 
derivative (a) in the presence of aluminium chloride and anhydrous diethyl ether as solvent, 
followed by a intramolecular cyclization (b). 
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The xanthone synthesis via diaryl ether (Figure 11, II) is an Ullman condensation of 
sodium phenolates with ortho-halogenated benzoic acids (c), followed by ring formation by 
electrophilic cycloacylation of the 2-aryloxybenzoic acids (d). 
Once intermolecular acylations give generally higher yields than Ullmann ether syntheses, 
the chosen route for xanthone synthesis is usually the acylation, followed by cyclization to form 
the heterocyclic ring (Sousa, M.E. and Pinto, M., 2005). 
 
 
 
 
 
Figure 11. Synthesis of xanthones via benzophenone and via diaryl ethers intermediate 
 
Different methods of construction of xanthone core have been reported in the last years. 
Modifications to the GSS reaction (Figure 10) have emerged.  For example, in some cases, better 
results can be obtained using as catalyst the Eaton’s reagent (phosphorus pentoxide and 
methanesulfonic acid) instead of the traditional mixture of phosphorus oxychloride and zinc 
chloride (Davies, J.S.H. et al., 1958; Grover, P.K. et al., 1955; Pillai, R.K.M. et al., 1986; Sousa, M.E. 
and Pinto, M., 2005). Later, this alternative method will be discussed in this thesis applied to the 
xanthone synthesis. 
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 Very recently, Verbanac (Verbanac, D. et al., 2012) described an efficient microwave-
assisted chemical synthesis of (thio)xanthones. According to them, from a mixture of phenolic 
acids and phenol derivatives with Lewis acid (Figure 12), heated under microwave irradiation, 
xanthones can be obtained with the desired regioselectivity in a shorter reaction time (50 
seconds) and with very good yields (upper than 80%). 
 
 
 
Figure 12.  Xanthone synthesis by Verbanac, D. et al., 2012 
 
 
 
Others methodologies for the synthesis of xanthones can be found in a very recent review 
by Key-Simeon Masters and Stefan Bräse (Masters, K-S. and Bräse, S., 2012). 
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4. SYNTHESIS OF PRENYLATED XANTHONES 
 
4.1. “CLASSICAL” SYNTHETIC METHODOLOGIES 
 
The methodologies to obtain synthetic prenylated xanthones and respective cyclic 
derivatives are based on different approaches of molecular modification (Pinto, M. and 
Castanheiro, R., 2009a) namely: 
• Molecular extension through prenylation of xanthonic scaffold (Figure 13); 
• Molecular rigidification by Claisen rearrangement and/or cyclization of prenylated 
precursors (Figures 14 and 15).  
 
 
4.1.1. Molecular extension through  prenylation of xanthonic scaffold 
 
 The xanthonic scaffold can be prenylated by a nucleophilic substitution reaction with 
prenyl bromide, in alkaline medium. The products of this reaction are usually prenyloxy 
xanthones, however, in some cases, diprenylated derivatives with the prenyl group on the carbon 
adjacent to the prenyloxy substituent can also be obtained (Figure 13 (i)). If the reaction is 
performed in an aqueous medium, for example a KOH solution, C-prenylation can also occur 
(Figure 13 (ii)) (Pinto, M. and Castanheiro, R., 2009a). 
 
 
 
(i) Prenyl bromide, K2CO3, Acetone, reflux, 8h (2, 48%; 3, 3%) 
 
 
 
(ii) Prenyl bromide, aq. KOH 10%, room temperature, overnight (5, 11%; 6, 13%; 7, 10%). 
 
Figure 13. Prenylation of the xanthonic scaffold with different experimental conditions (i, ii). 
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4.1.2. Molecular rigidification by Claisen rearrangement and/or cyclization of prenylated 
precursors 
 
 
• Claisen rearrangement of prenylated precursors 
 
The molecular rigidification can be the result of Claisen rearrangement. In figure 14 (i), 
the 1-hydroxy-3-(3-methylbut-2-enyloxy)-9H-xanthen-9-one (8) were heated in vacuum at 200-
210°C to obtain rearranged prenyl xanthones and/or cyclic derivatives. Three products were 
formed: 1,3-dihydroxy-9H-xanthen-9-one (9), and two products with 4,4,5-trimethyl-4,5-
dihydrofuran-ring condensed in either linear (10) or angular ways (11). These dihydrofuran 
derivatives results of Claisen rearrangement in both the available ortho positions of the xanthone 
scaffold to give (1,1-dimethylallyl) derivatives (Figure 3, C) followed by spontaneous cyclization 
involving the 3-hydroxy group (Pinto, M. and Castanheiro, R., 2009a). 
 
 
(i) Vacuum, 200-210°C (9, 32%; 10, 18%; 11, 9%) 
 
 
(ii) N,N-DMA, 200°C (13, 60%; 14, 30%) 
 
Figure 14. Claisen rearrangement of prenylated precursors 
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Other example of the Claisen rearrangement is the reaction of 3-methoxy-1-(3-methylbut-
2-enyloxy)-9H-xanthen-9-one (12) performed in N,N-dimethylaniline (N,N-DMA) (Figure 14 (ii)). A 
mixture of 1-hydroxy-3-methoxy-4-(3-methylbut-2-enyl)-9H-xanthen-9-one (13) and the 
dihydrofuranoxanthone (14) were obtained, along with a small amount of starting material (12). 
The xanthone 13 resulted of a para Claisen rearrangement of xanthone 12, while 
dihydrofuranoxanthone 14 was obtained from an ortho Claisen rearrangement followed by a 
spontaneous cyclization with the 1-hydroxy group (Pinto, M. and Castanheiro, R., 2009a). 
 
 
 
 
• Cyclization of prenylated precursors 
 
The molecular rigidification can also be the result of cyclization of prenylated precursors. 
In figure 15, the monoprenylated xanthone 2 is used as precursor for the synthesis of 
dihydropyranoxanthones. By heating 2 with zinc chloride in o-xylene, the angular 
dihydropyranoxanthone 15 is obtained (Pinto, M. and Castanheiro, R., 2009a; Castanheiro, R. et. 
al., 2009b).  
 
 
(i) ZnCl2, o-xylene, 200°C, 21h (15, 22%) (Castanheiro, R. et. al, 2009b) 
 
Figure 15. Synthesis of dihydropyranoxanthones 
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4.1.3. Different approaches for the synthesis of prenylated xanthones 
 
Prenylated xanthones can also be generated by a condensation and consequent 
cyclization reaction of prenylated building blocks. For example, using this method the naturally 
occurring α-mangostin (Figure 16, 20) can be synthesized. The coupling reaction between the 
building blocks (16 and 17) leads to benzophenone intermediate (19) that cyclizes, to give the 
natural xanthone (20) (Pinto, M. and Castanheiro, R., 2009a). 
 
 
 
 
 
Figure 16. Synthesis of α-mangostin (i): sBuLi, THF, -78°C, 49%; (ii) IBX, toluene/DMSO (1/1), room 
temperature, 76%; (iii) 10% Pd/C, HCO2NH4, acetone, room temperature, 63%; (iv) PPh3, CCl4, THF, 
room temperature, silica gel, 43% 
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4.2. “NON-CLASSICAL” SYNTHETIC METHODOLOGIES 
 
The synthetic procedures can be achieved not only by the application of classical 
methodologies, such as the use of conventional heating, but more recently following “non-
classical” synthetic alternatives like microwave-assisted organic synthesis (MAOS) and/or 
heterogeneous catalysis. In this thesis, the molecular modifications to obtain prenylated 
xanthones were attained by the application of these two techniques discussed later on. 
To quickly and efficiently synthesize a large number of xanthones derivatives, alternative 
synthetic methodologies to the classical ones are being increasingly explored. The lack of 
reproducibility, difficult and expensive scale-up and standardization of synthetic processes are the 
main hurdles towards the industrial production. Time- and energy-consuming synthetic routes, 
usually involving the use of volatile and toxic organic solvents, can be apparently cost-viable and 
environmentally acceptable for the synthesis at a laboratory scale. However, in an industrial scale, 
due to the product high cost and to the negative impact they cause on the environment, that 
routes are often not viable. Also, the appearing of a new philosophy that aims to minimize the use 
of non-renewable resources and organic solvents, the generation of toxic secondary products and 
the consumption of energy and the emission of gases – the so called green chemistry or 
sustainable chemistry, a concept that has received enormous attention in recent times - has 
encouraged the use of “non-classical” synthesis (Sosnik, A. et al., 2011). 
To overcome those hurdles and achieved the aims of the green chemistry, synthetic 
alternatives like microwave-assisted organic synthesis (MAOS) and heterogeneous catalysis are 
being applied. 
 
 
• MAOS - Microwave-assisted organic synthesis 
 
MAOS, first reported in the late 1980s, relies on the application of microwave (MW) 
irradiation as the energy source for organic reactions. MWs comprise electromagnetic radiation 
with a frequency between 0.3 and 300 GigaHertz (GHz), with domestic and synthetic ovens 
usually opperating between 2 and 8 GHz (Figure 17). 
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Figure 17. Electromagnetic spectrum (http://labs.ciid.dk/experiments/) 
 
 
MAOS is mainly based on the efficient heating of materials by microwave dielectric 
heating effects. Microwave dielectric heating is dependent on the ability of a specific material 
(solvent or reagent) to absorb microwave energy and convert it to heat. The ability to convert 
MW energy into heat, at a given frequency and temperature, is determined by the dissipation 
factor or ‘loss tangent’, tan δ and in general a reaction medium with a high (>0.5) tan δ value, at 
the standard operating frequency of a microwave synthesis reactor (2.45 GHz), is required for 
efficient absorption and rapid heating (Kappe, C.O., 2008).  
Microwave irradiation triggers heating by two main mechanisms— dipolar polarization 
and ionic conduction. Whereas the dipoles in the reaction mixture (for example the polar solvent 
molecules) are involved in the dipolar polarization effect, the charged particles in a sample 
(usually ions) are affected by ionic conduction. When irradiated at microwave frequencies, the 
dipoles or ions of the sample align in the applied electric field. As the applied field oscillates, the 
dipole or ion field attempts to realign itself with the alternating electric field and, in the process, 
energy is lost in the form of heat (Figure 18).  
Although is not the only important factor in the conversion of energy into heat, the 
polarity of the solvent is an important tool to predict if the solvent will be heated under MW 
irradiation. Usually, polar solvents absorb well MW irradiation, while less polar or non-polar 
solvents are low absorbing or do not absorb. If the reaction requires the use of solvents that are 
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non-polar and therefore MW low absorbing, there are passive heating elements, like weflonTM 
(inert phluoropolymer) magnetic bars, that are made out of strongly microwave absorbing 
materials and therefore increase the MW absorbance level of the medium, allowing the heating 
of the mixture reaction (Kappe, C.O., 2008; http://www.milestonesci.com).  
 
Figure 18. Dipolar polarization; microwave versus traditional heating process 
 
 
Until recently, heating reaction mixtures on a laboratory scale was typically performed 
using isomantles, oil baths or hot plates applying a reflux set-up where the reaction temperature 
is controlled by the boiling point of the solvent. This traditional form of heating – surface heating - 
is a rather slow and inefficient method for transferring energy into a reaction mixture and often 
results in the temperature of the reaction vessel being higher than that of the reaction mixture. In 
contrast, microwave irradiation produces efficient internal heating by direct coupling of 
microwave energy with the molecules present in the reaction mixture (Figure 18) (Kappe, C.O., 
2008; Salema, A.A. and Ani, F.N., 2011; Sosnik, A. et al., 2011). Since the reaction vessels 
employed in microwave chemistry are made out of essentially microwave transparent materials 
such as glass or Teflon only the reaction mixture is heated. 
 
 The equipment used in this work was the MicroSYNTH from Milestone. There are 
different adaptable accessories to thus equipment, allowing it to be used widely, in a small or 
large scale, at different values of pressure and temperatures. The inside temperature of the vessel 
is measured by an optic fiber sensor and the outside temperature, in the cavity, is controlled 
through an infrared sensor (Figure 19) (Favretto, L., 2003; http://www.milestonesci.com). 
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Figure 19. MW equipment system (http://www.milestonesci.com) 
 
Due to unique advantages such as shorter reaction times, higher yields, limited generation 
of by-products and the relatively easy scale-up without detrimental effects, this technology has 
steadily become an appealing synthetic tool (Kappe, C.O. and Dallinger, D., 2009; Kappe, C.O., 
2008 and 2004; Sosnik, A. et al., 2011). 
 
Comparing the results and reaction conditions with the reaction presented before in 
Figure 13 (i), it is notably the optimization of the synthetic process when MW irradiation was 
applied (Figure 20). This reaction was faster, with better yields and more selectivity as we can 
conclude by the analysis of table 2 (Pinto, M. and Castanheiro, R., 2009a). 
 
 
 
 
 
 
Figure 20. Prenylation using MAOS (i) Prenyl bromide, K2CO3, Acetone, MW, 200W, 3x20min, 59°C 
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Table 2. Prenylation through MW irradiation and conventional heating 
 
Conventional Heating MW 
Yield 
48% (2)  
  3% (3) 
83%(2) 
 5% (3) 
Reaction time 8 h 1h 
 
 
The microwave heating process, the high temperatures attained and the ability to work 
under high pressure conditions for relatively short times make reactions faster than under 
conventional thermal conditions and limit the occurrence of side reactions (Salema, A.A. and Ani, 
F.N., 2011; Kappe, C.O., 2008 and 2004). Therefore, better yields, more selectivity and reaction 
times reduced from days and hours to minutes and seconds represent a big gain in areas like 
Medicinal Chemistry and Drug Discovery, where large libraries of compounds are generated. 
In table 3 are summarized some relevant differences between conventional thermal 
heating and MW heating (the differences need to be understood as general) (Sosnik, A. et al., 
2011). 
Table 3. Main general differences between conventional and MW heating (Sosnik, A., et al., 2011). 
PROPERTY CONVENTIONAL HEATING MW HEATING 
Heating rate  Slow Fast 
Maximum reaction 
temperature 
Limited by the bp* of the solvent 
(reflux) 
Overheating above bp* (up to 
100°C in a closed-vessel) 
Reaction time (rt) Long  Short  
Pressure High pressure reactions more 
dangerous (longer reaction time) 
High pressure reactions are 
safer 
Homogeneity of heating Low High 
Yield Low High 
Amount of secondary products High Low 
Solvent conditions Difficult to work without solvent Easy to work in solvent-free 
conditions 
Reproducibility 
a
 Low High 
*bp – boiling point 
a 
A higher reproducibility of MW reactions is commonly claimed, but this depends on the sophistication of the 
equipment, as domestic MW ovens lack optimal reproducibility. 
Other advantage of MW technique is, when one of the reactants is liquid, it can act as a 
solvent and absorb MW irradiation sufficiently to heat the system, so that reactions can be 
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conducted under solvent-free conditions (Bougrin, K. et al., 2005; Kappe, C.O. and Dallinger, D., 
2009; Kappe, C.O., 2004).  Due to environment and economical advantages, solvent-free reactions 
are becoming more appealing, optimizing conventional procedures, by turning them cleaner, 
safer and simpler. Syntheses traditionally with long reaction times can sometimes become faster 
when MW and solvent-free conditions are associated. Today, more therapeutic targets are being 
identified and the synthesis and optimization of lead compounds have to be accelerated (Kappe, 
C.O. and Dallinger, D., 2005). The traditional synthesis is usually slow and can be insufficient to 
satisfy the growing need of new drugs. In this context, MW and solvent-free methods have high 
potential in accelerating this discovery. Avoid the use of organic solvents leads to cleaner, cheaper 
and efficient syntheses (Green Chemistry), with good yields and short reaction times (Verbanac, 
D. et al., 2012). 
MW irradiation has shown many advantageous features over the conventional methods 
and, even if the experimental conditions to expand its applications in industry remain to be 
optimized, it is obvious that MW represents one the most versatile and promising synthetic and 
processing technologies available today (Sosnik, A. et al., 2011). 
 
• Heterogeneous Catalysis 
 
Nowadays, one of the biggest challenges in chemistry is to develop synthetic routes that 
are less polluting, designing clean or green chemical transformations that should not cause 
permanent damage to the environment. Ways to minimize the consumption of energy and raw 
materials must be deployed so that optimal value of resources could be realized and 
environmentally friendly products can be obtained at reasonable costs – Green Chemistry. 
Catalysts can be a great help to achieve many of these goals (Zhou, C.H., 2011). 
Catalysts could be synthetic or natural chemicals capable of making an otherwise 
impracticable reaction to occur under the mildest possible conditions. Recently, an important 
family of catalysts derived from the soil has raised the interest of the chemists, being the most 
remarkable ones the clays and zeolites (Nagendrappa, G., 2011 and 2002). The commercially 
available montmorillonite K10 clay was one of the chosen catalysts to work with. 
Clays are widespread, easily available and low-cost chemical substances. Both in their 
native state and in numerous modified forms, clays are versatile materials that can function as 
Brönsted and/or Lewis acids, or as bases and are used to catalyze various types of organic 
reactions, usually allowing higher yields and greater selectivity (Nagendrappa, G., 2011). 
Clays are aluminosilicate nanoparticles (<2 mm in diameter) with layered structures and a 
surface area of about 23000 cm2 per gram. The layers possess net negative charge that is 
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neutralized by cations such as Na+, K+, Ca2+, which occupy the interlamellar space and can be very 
easily replaced by other cations or other molecules. Therefore, simple procedures can easily alter 
clays properties like acidity, pore size, surface area and others, turning clays, in addition to their 
environmental compatibility and cheapness, in a catalyst of choice. 
Several reviews have been written about clays, highlighting the advantages and 
developments in the area of organic synthesis using clays (Varma, R.S., 1999; Zhou, C.H., 2011). 
Their chemical composition and crystal structure are the basis on which they are divided into 
four main groups such as illite, smectite, vermiculite, and kaolinite. In clays groups, the one 
that is found to be most useful as a catalyst to the synthetic organic chemist is a subgroup of the 
smectite clay, called montmorillonite. The montmorillonite lattice is composed of a octahedral 
sheet of [Al2(OH)6] between two tetrahedral sheets of [SiO4]
4- (Figure 21). The three-sheet layer 
repeats itself, and the interlayer space holds the key to the chemical and the physical properties 
of the clay, once, like said before, it has cations that can be replaced by other cations or 
molecules. 
 
 
 
Figure 21. Structure of montmorillonite (Nagendrappa, G., 2002) 
 
 When the clay is dry these cations reside in the hexagonal cavities of the silica sheets. 
When wet, the layers of the clay move apart by the entry of water molecules, the clay swells and 
the interlayer cations become easily exchangeable by a variety of metallic and non-metallic 
cations, for example H3O
+, NH4
+, Al3+, Fe3+. Therefore the catalytic properties of montmorillonite 
clay can be manipulated to meet the needs of synthetic organic chemists and a variety of organic 
reactions can be carried out with great success using such clays as catalysts. With clays, reactions 
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take place more efficiently, under milder conditions, with better yields, shorter reaction times and 
greater product selectivity. 
 
Figure 22 shows an example of a prenylation reaction of xanthone 1 that occurred in the 
presence of K10 clay. Different reaction conditions – room temperature (A), conventional heating 
at 100 °C (B) and MW irradiation (C) were tested. By analysis of table 4, it is clear that the 
combination of K10 clay-catalysis with MW irradiation was the better method to obtained 
dihydropyranoxanthone 15 (better yields and shorter reactions times). 
 
 
 
 
Figure 22. Clay-catalyzed condensation (i) K10 Clay, CHCl3, prenyl bromide, stirring, heating 
(Castanheiro, R. et al., 2009b) 
 
 
 
 
 
Table 4. Yields obtained with different reaction conditions (Castanheiro, R. et al., 2009b)
Method 
Reaction 
time 
Temperature 
Yields with K10 
clay 
Yield with classical synthetic 
method 
A 5 days 
Room 
temperature 
51% 
 
 
10,5% 
B 60 minutes 100°C 63% 
C with solvent 20 minutes 110°C 53% 
C without 
solvent 
20 minutes 105°C 86% 
 
 
 
Besides these, clays have others advantages. The work-up and purification are simpler, 
because the clay is separated easily from the reaction mixture and the catalyst can be reused or 
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regenerated (Nagendrappa, G., 2002). For all this, the clay-catalyzed synthesis is economical and 
environmentally favourable, representing a great advantage in a moment where there is urgent 
to replace the not-so-desirable conventional catalysts by the called green catalysts. 
In this thesis, the chemical syntheses catalyzed by montmorillonite K10 clay were 
performed under microwave irradiation. Associating MW irradiation with inorganic solid supports 
such as clays, either with solvent or under solvent-free conditions, can bring advantages to the 
chemical synthesis once it usually allows better reaction rates, high yields, ease of manipulation 
and selectivity (Castanheiro, R. et al., 2009b; Nagendrappa, G., 2011; Varma, R.S., 1999). 
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II. AIMS 
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AIMS 
 
 
 This thesis had the main goal the synthesis of xanthone derivatives with prenyl 
substituents, either in a cyclic or as an open-chain form, and to evaluate their biological activity, 
namely antitumor. Different synthetic methodologies were applied, considering the principles of 
the Green Chemistry. To elucidate the structure of the new obtained compounds, spectroscopic 
methods were a useful tool. 
 Based on these, the aims of this thesis were: 
 
- To synthesize the building block 1,3-dihydroxy-5-methoxyxanthone; 
- To obtained new prenylated xanthone derivates – cyclic and/or open-chain; 
- To apply different methodologies to the synthesis of xanthones derivatives  – “classical” 
and “non-classical” – to attempt better yields, shorter reactions times, more selectivity, 
lower costs and less environmental danger; 
        -     To elucidate the structures of the new compounds using analytical techniques, namely IR,   
              HRMS and NMR (1H, 13C, HSQC and HMBC); 
- To evaluate the biological activity of the synthesized compounds, namely the antitumor 
activity, through their effect on the in vitro growth of three human tumor cell lines, MCF- 
7 (breast adenocarcinoma), NCI-H460 (non-small cell lung cancer) and A375-C5 (malignant 
melanoma). 
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RESULTS AND DISCUSSION 
 
1. Synthesis of xanthone derivatives 
 
PART I 
Synthesis of 1,3-dihydroxy-5-methoxyxanthone 
 
 The 2-hydroxy-3-methoxybenzoic acid and phloroglucinol (1,3,5-trihydroxybenzene) were 
used as starting materials for the synthesis of 1,3-dihydroxy-5-methoxyxanthone (X1). This 
xanthonic building block (X1) was synthesized through the Grover, Shah and Shah (GSS), method 
A (Figure 23), and also applying Eaton’s reagent (P2O5/CH3SO3H) (B) as the condensation agent 
(Figure 24), both with conventional heating (Grover, P.K. et al., 1955; Davies, J.S.H. et al., 1958; 
Pillai, R.K.M. et al., 1986). 
In method A (GSS reaction), the use of ZnCl2 and POCl3 results in better yields, obtaining 
the 1,3-dihydroxy-5-methoxyxanthone (X1) with 39% yield. 
 
 
Figure 23. Synthesis of 1,3-dihydroxy-5-methoxyxanthone through method A (ZnCl2, POCl3,70°C, 
4h30) 
 
 
In method B (Eaton’s reaction) (Figure 24), due to different reaction conditions, two 
different xanthones were obtained: 1,3-dihydroxy-5-methoxyxanthone (X1) and 1-hydroxy-3-
mesyloxy-5-methoxyxanthone (X2), with 23% and 15% yield, respectively. 
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Figure 24. Synthesis of 1,3-dihydroxy-5-methoxyxanthone through method B (P2O5, CH3SO3H, 
100°C, 1h) 
 
The purification of X1 and X2 was performed by flash column chromatography, using flash 
silica gel as stationary phase and a gradient of chloroform/acetone as mobile phase. After 
crystallization from methanol, yellow crystals of both compound X1 and X2 were obtained. 
 
 
PART II 
Synthesis of prenylated xanthones 
 
To synthesize prenylated xanthones, the first synthetic approach involves the nucleophilic 
substitution on the xanthonic building block 1,3-dihydroxy-5-methoxyxanthone (X1), with prenyl 
bromide in alkaline medium (Cs2CO3) using acetone as solvent, under 200W microwave irradiation 
for 1 hour. In this procedure, two main prenylated derivatives were obtained: 1-hydroxy-5-
methoxy-3-(3-methylbut-2-enyloxy)xanthone (P1) and 1-hydroxy-5-methoxy-4-(3-methylbut-2-
enyl)-3-(3-methylbut-2-enyloxy)xanthone (P2) in 15% and 5% yield, respectively (Figure 25). Other 
two products were detected but in such small percentage that could not be isolated. 
 
 
 
Figure 25. General procedure for the synthesis of P1 and P2 by MW irradiation (i) Prenyl bromide, 
Cs2CO3, Acetone, MW, 200W, 1h 
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The second synthetic approach involves a combined methodology using MAOS and 
montmorillonite K10 clay. 
The 1,3-dihydroxy-5-methoxyxanthone (X1) was prenylated in the presence of 
montmorillonite K10 clay, using chloroform as solvent, under 180W microwave irradiation for 45 
minutes (Figure 26). In this clay-catalyzed synthesis, three main prenylated derivatives were 
obtained, along with a small amount (13% yield) of starting material: 1-hydroxy-5-methoxy-4-(3-
methylbut-2-enyl)-6’,6’-dimethyl-4’,5’-dihydropyran(2’,3’:3,2)xanthone (P3, 0.3% yield), 1-
hydroxy-5-methoxy-6’,6’-dimethyl-4’,5’-dihydropyran(2’,3’:3,2)xanthone (P4, 3% yield) and 1-
hydroxy-5-methoxy-6’,6’-dimethyl-4’,5’-dihydropyran(2’,3’:3,4)xanthone (P5, 13% yield). Other 
two products were detected but in such small percentage that could not be isolated. 
 
 
 
Figure 26. General procedure for the synthesis of P3, P4 and P5 by MW irradiation (ii) Prenyl 
bromide, montmorillonite K10 clay, Chloroform, MW, 180W, 45min  
 
 
 The purification of these prenylated xanthone derivatives was performed by flash column 
chromatography and preparative TLC (SiO2; hexane/ethyl acetate), and through crystallization. 
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2. STRUCTURE ELUCIDATION 
 
 The structure elucidation of X1, X2, P1, P2, P3, P4 and P5 was established on the basis of 
melting point, IR, HRMS and NMR (1H, 13C, HSQC and HMBC) techniques.  
 
 
 By the analysis of the IR data, all compounds (X1, X2, P1, P2, P3, P4 and P5) show the 
presence of a band at 3500-3400cm-1 corresponding to O-H stretch of hydroxyl groups. It is 
possible to observe a band corresponding to the C=O, as well as bands corresponding to the C-C 
aromatic bond typical from the xanthone scaffold. As expected, in P1 to P5, the IR data show the 
presence of additional bands, corresponding to the C-C and C-H bonds of the prenyl group. 
Nevertheless, prenylation did not occurred for all hydroxyl groups, once there is still present the 
band at 3500-3400 cm-1, characteristic of OH group. 
 
 
The EI-HRMS gave the accurate molecular mass of the compounds and their molecular 
formula: 
 
X1 -EI-HRMS m⁄z  found for C14H10O5  : 258.0530; 
X2- EI-HRMS m⁄z  found for C15H12O7S  : 336.0305; 
P1 - EI-HRMS m⁄z  found for  C19H18O5  : 326.1157; 
P2 - EI-HRMS m⁄z  found for  C24H26O5  : 394.1769; 
P3 – not determined; 
P4 – EI-HRMS m⁄z found for C19H18O5  : 326.1153; 
P5 - EI-HRMS m⁄z found for C19H18O5  : 326.1157. 
 
 
The 1H NMR and 13C NMR data of X1, X2, P1, P2, P3, P4 and P5 are presented in tables 5 
to 18.  
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Table 5. 1H NMR data for compound X1 
 
                                       X1                                        δH 
H-2 6.22 (1H, d, J= 2.1) 
H-4 6.41 (1H, d, J= 2.1) 
H-6 7.50 (1H, dd, J= 8.0 and 1.4) 
H-7 7.38 (1H, t, J= 8.0) 
H-8 7.66 (1H, dd, J= 8.0 and 1.4) 
O-H1 12.82 (1H, s) 
O-H3 - 
OCH3 3.97 (3H, s) 
¥ Values in ppm (δH) relative to Me4Si as an internal reference. J values are in Hz. 
 
 
 
Table 6. 13C NMR data for compound X1 
 
                                       X1                                       δC 
C-1 162.8 
C-2 98.3 
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C-3 166.1 
C-4 94.2 
C-4a 157.2 
C-5 147.9 
C-6 116.7 
C-7 124.1 
C-8 115.7 
C-8a 120.6 
C-9 179.8 
C-9a 102.1 
C-10a 145.4 
OCH3 56.2 
¥ Values in ppm (δC). 
 
 
 
Table 7. 1H NMR data for compound X2 
   
                                        X2                                           δH 
H-2 6.83 (1H, d, J= 2.1) 
H-4 7.18 (1H, d, J= 2.1) 
H-6 7.58 (1H, dd, J= 8 and 1.5) 
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H-7 7.45 (1H, t, J= 8.0) 
H-8 7.71 (1H, dd, J= 8.0 and 1.5) 
O-H1 12.79 (1H, s) 
OCH3 3.99 (3H, s) 
OSO2CH3 3.53 (3H, s) 
¥ Values in ppm (δH) relative to Me4Si as an internal reference. J values are in Hz. 
 
 
 
Table 8. 13C NMR data for compound X2 
   
                                     X2                                            δC 
C-1 162.2 
C-2 104.6 
C-3 154.8 
C-4 101.6 
C-4a 156.2 
C-5 148.1 
C-6 117.5 
C-7 124.8 
C-8 115.8 
C-8a 120.6 
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C-9 181.1 
C-9a 107.3 
C-10a 145.7 
OCH3 56.4 
OSO2CH3 37.9 
¥ Values in ppm (δC).  
 
The 1H NMR spectra of compounds X1 and X2 showed five signals corresponding to 
aromatic protons, namely H-2 and H-4 and H-6, H-7, H-8. The group OCH3 was confirmed by the 
existence of a singlet due to three protons at 3.97 and 3.99 ppm, respectively 3.9 ppm. The signal 
for the protons of hydroxyl groups (OH1) appeared as a singlet at 12.82 and 12.79 ppm, 
respectively. In compound X2, the protons of the group OSO2CH3 appeared as a singlet at 3.53 
ppm. 
The 13C NMR spectra of X1 and X2 revealed signals that correspond to the carbon atom of 
the carbonyl group (δC 179.8 and 181.1, respectively) and to two aromatic rings (values of δC 
between 98.3 and 145.4 ppm for compound X1 and between 104.6 and 145.7 ppm for compound 
X2; corresponding to twelve carbons). The signal for the carbon of OCH3 group appeared at δC 
56.2 and 56.4 ppm, respectively, and in compound X2 the carbon of the mesyl group appeared at 
37.9 ppm. 
 
 
Table 9. 1H NMR data for compound P1 
      
                                           P1                                               δH  
H-2 6.36 (1H, d, J= 2.3) 
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H-4 6.54 (1H, d, J= 2.3) 
H-6 7.22 (1H, dd, J=8.0 and 1.7) 
H-7 7.29 (1H, t, J=8.0) 
H-8 7.81 (1H, dd, J=8.0 and 1.7) 
O-H1 12.81 (1H, s) 
OCH3 4.03 (3H, s) 
H-1’ (H prenyl) 4.59 (2H, d, J=6.7) 
H-2’ (H prenyl) 5.50 (1H, t, J=6.7) 
H-4a’ and H-4b´ (H prenyl) 1.82 (3H, s) and 1.76 (3H, s) 
¥ Values in ppm (δH) relative to Me4Si as an internal reference. J values are in Hz. 
 
 
 
Table 10. 13C NMR data for compound P1 
      
                                       P1                                          δC 
C-1 163.2 
C-2 98.2 
C-3 166.1 
C-4 93.3 
C-4a 157.5 
47 
 
C-5 148.2 
C-6 115.6 
C-7 123.5 
C-8 116.7 
C-8a 121.5 
C-9 180.7 
C-9a 103.8 
C-10a 146.3 
OCH3 56.4 
C-1’ (prenyl) 65.5 
C-2’ (prenyl) 118.5 
C-3’ (prenyl) 139.3 
C-4a’ and C-4b’ (prenyl) 25.8 and 18.3 
¥ Values in ppm (δC). 
 
The 1H NMR spectrum of P1 showed five signals corresponding to aromatic protons, 
namely H-2 and H-4 and H-6, H-7, H-8 (values of δH between 6.36 and 7.81 ppm). The group OCH3 
was confirmed by the existence of a singlet due to three protons at 4.03 ppm. The signal for the 
protons of hydroxyl group appeared as a singlet (δH 12.81 ppm). The presence of the prenyl group 
was confirmed by the existence of a duplet and a triplet corresponding to the protons H-1’ and H-
2’ (δH 4.59 and 5.50 ppm, respectively) and the signal for the protons of two methyl groups 
appearing as a singlet (δH 1.82 and 1.76 ppm). 
The 13C NMR spectrum revealed signals that correspond to the carbon atom of the 
carbonyl group (δC 180.7 ppm) and to two aromatic rings (values of δC between 98.2 and 146.3 
ppm; corresponding to twelve carbons). The signal for the carbon of OCH3 group appeared at δC 
56.4 ppm. The spectrum also revealed signals of the five carbons of the prenyl group. 
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Table 11. 1H NMR data for compound P2 
 
                                    P2                                           δH 
H-2 6.39 (1H, s) 
H-6 7.21 (1H, dd, J=7.9 and 1.8) 
H-7 7.27 (1H, t, J=7.9) 
H-8 7.79 (1H, dd, J=7.9 and 1.8) 
O-H1 12.96 (1H, s) 
OCH3 3.99 (3H, s) 
H-1’ (H prenyl) 4.63 (2H, d, J=6.6) 
H-2’ (H prenyl) 5.50 (1H, t, J=6.6) 
H-4a’ and H-4b’ (H prenyl) 1.81 (3H, s) and 1.76 (3H, s) 
H-1” (H prenyl) 3.55 (2H, d, J=7.4) 
H-2” (H prenyl) 5.30 (1H, t, J=7.4) 
H-4a” and H-4b” (H prenyl) 1.87 (3H, s) and 1.67 (3H, s) 
¥ Values in ppm (δH) relative to Me4Si as an internal reference. J values are in Hz. 
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Table 12. 13C NMR data for compound P2 
      
                                        P2                                         δC 
C-1 161.7 
C-2 95.2 
C-3 163.7 
C-4 108.4 
C-4a 153.8 
C-5 148.7 
C-6 115.6 
C-7 123.2 
C-8 116.5 
C-8a 121.2 
C-9 181.3 
C-9a 103.4 
C-10a 146.7 
OCH3 56.2 
C-1’ (prenyl) 65.7 
C-2’ (prenyl) 119.0 
C-3’ (prenyl) 138.5 
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C-4a’ and C-4b’ (prenyl) 25.8 and 18.3 
C-1” (prenyl) 21.8 
C-2” (prenyl) 122.2 
C-3” (prenyl) 131.7 
C-4a” and C-4b” (prenyl) 25.9 and 17.6 
¥ Values in ppm (δC). 
 
The 1H NMR spectrum of P2, a diprenylated xanthone, showed four signals corresponding 
to aromatic protons of the phenyl rings, namely H-2 and H-6, H-7, H-8 (values of δH between 6.39 
and 7.79 ppm). The group OCH3 was confirmed by the existence of a singlet due to three protons 
at 3.99 ppm. The signal for the protons of hydroxyl group appeared as a singlet (δH 12.96 ppm). 
The presence of the prenyl groups was confirmed by the existence of two duplet corresponding to 
the protons H-1’ and H-1” (δH 4.63 and 3.55 ppm), of two triplet corresponding to the protons H-
2’ and H-2” (δH 5.50 and 5.30 ppm) and the signal for the protons of two methyl groups appearing 
as a singlet (δH 1.87 and 1.67 ppm). 
The 13C NMR spectrum of P2 revealed signals that correspond to the carbon atom of the 
carbonyl group (δC 181.3 ppm) and to two aromatic rings (values of δC between 95.2 and 146.7 
ppm; corresponding to twelve carbons). The signal for the carbon of OCH3 group appeared at δC 
56.2 ppm. The spectrum also revealed signals of the ten carbons of the two prenyl groups present 
in this compound. 
 
Table 13. 1H NMR data for compound P3 
O
O OH
O
OCH3
3`
2`
5`
6`
4`
1´´
2´´
3´´
4a´´ 4b´´
1
45
6
7
8
8a
10a
9a
4a 3
2
9
7a`
7b`
 
                               P3                                           δH 
H-6 7.22 (1H, dd, J=7.8 and 1.8) 
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H-7 7.30 (1H, t, J=7.8) 
H-8 7.81 (1H, dd, J=7.8 and 1.8) 
O-H1 13.10 (1H, s) 
OCH3 4.01 (3H, s) 
H-4’ (H dihydropyran)  2.17 (2H, t, J=6.8) 
H-5’ (H dihydropyran) 2.01 (2H, t, J=6.8) 
H-7a’ and H-7b’ (H dihydropyran) 1.38 (6H, s) 
H-1” (H prenyl) 3.98 (2H, d, J=7.4) 
H-2” (H prenyl) 6.26 (1H, t, J=7.4) 
H-4a” and H-4b” (H prenyl) 1.75 (6H, s) 
¥ Values in ppm (δH) relative to Me4Si as an internal reference. J values are in Hz. 
 
 
 
 
Table 14. 13C NMR data for compound P3 
    
O
O OH
O
OCH3
3`
2`
5`
6`
4`
1´´
2´´
3´´
4a´´ 4b´´
1
45
6
7
8
8a
10a
9a
4a 3
2
9
7a`
7b`
 
                                 P3                                         δC 
C-1 163.6 
C-2 95.1 
C-3 164.2 
C-4 108.1 
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C-4a 152.7 
C-5 148.4 
C-6 115.8 
C-7 123.4 
C-8 116.7 
C-8a 121.4 
C-9 180.8 
C-9a 103.4 
C-10a 146.1 
OCH3 56.6 
C-4’ (dihydropyran) 15.9 
C-5’ (dihydropyran) 31.6 
C-6’ (dihydropyran) 76.7 
C-7a’ and C-7b’ (dihydropyran) 26.2 
C-1” (prenyl) 28.6 
C-2” (prenyl) 94.3 
C-3” (prenyl) 135.4 
C-4a” and C-4b” (prenyl)  18.9 
¥ Values in ppm (δC).  
 
 
 
In the 1H NMR spectra of P3 the signal for the protons of hydroxyl group appeared as a 
singlet (δH 13.10) and the group OCH3 was confirmed by the existence of a singlet due to three 
protons at 4.01 ppm. The spectra also show three signals corresponding to aromatic protons H-6, 
H-7, H-8 (values of δH between 7.22 and 7.81 ppm).  
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The presence of the prenyl group was confirmed by the existence of a duplet and a triplet 
corresponding to the protons H-1’’ and H-2’’ (δH 3.98 and 6.26 ppm, respectively) and the signal 
for the protons of two methyl groups appearing as a singlet (δH 1.75 ppm). The presence of a 
fused dihydropyran ring was confirmed by the existence of two triplets due to two methylene 
protons (H-4’ and H-5’: δH 2.17 and 2.01 ppm) and the signal for the protons of two methyl groups 
appearing as a singlet (δH 1.38 ppm). 
The 13C NMR spectra of P3 revealed signals that correspond to the carbon atom of the 
carbonyl group (δC 180.8 ppm) and to two aromatic rings (values of δC between 95.1 and 164.2 
ppm). The signal for the carbon of OCH3 group appeared at δC 56.6 ppm. The spectrum revealed 
signals of the ten carbons of the two prenyl groups present in this compound. 
 
 
Table 15. 1H NMR data for compound P4 
                     
3`
2`
5`
6`
4`
O
O OH
O
OCH3
1
45
6
7
8
8a
10a
9a
4a 3
2
9
7a`
7b`
  
                                         P4                                     δH 
H-4 6.46 (1H, s) 
H-6 7.21 (1H, dd, J=8.0 and 1.8) 
H-7 7.27 (1H, t, J=8.0) 
H-8 7.81 (1H, dd, J=8.0 and 1.8) 
O-H1 13.20 (1H, s) 
OCH3 4.01 (3H, s) 
H-4’ (H dihydropyran) 2.74 (2H, t, J=6.8) 
H-5’ (H dihydropyran) 1.85 (2H, t, J=6.8) 
H-7a’ and H-7b’ (H dihydropyran) 1.38 (6H, s) 
¥ Values in ppm (δH) relative to Me4Si as an internal reference. J values are in Hz. 
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Table 16. 13C NMR data for compound P4 
     
3`
2`
5`
6`
4`
O
O OH
O
OCH3
1
45
6
7
8
8a
10a
9a
4a 3
2
9
7a`
7b`
  
                                         P4                                    δC 
C-1 160.4 
C-2 104.2 
C-3 161.9 
C-4 95.4 
C-4a 155.3 
C-5 148.2 
C-6 115.5 
C-7 123.1 
C-8 116.7 
C-8a 121.4 
C-9 180.8 
C-9a 102.8 
C-10a 146.4 
OCH3 56.4 
C-4’ (dihydropyran) 16.0 
C-5’ (dihydropyran) 31.7 
C-6’ (dihydropyran) 76.3 
C-7a’ and C-7b’ (dihydropyran) 26.7 
¥ Values in ppm (δC). 
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Table 17. 1H NMR data for compound P5 
  
                                       P5                                         δH 
H-2 6.26 (1H, s) 
H-6 7.22 (1H, dd, J=7.9 and 1.7) 
H-7 7.29 (1H, t, J=8.0) 
H-8 7.82 (1H, dd, J=7.9 and 1.7) 
O-H1 12.61 (1H, s) 
OCH3 4.02 (3H, s) 
H-4’ (H dihydropyran)  2.93 (2H, t, J=6.8) 
H-5’ (H dihydropyran) 1.89 (2H, t, J=6.8) 
H-7a’ and H-7b’ (H dihydropyran) 1.39 (6H, s) 
¥ Values in ppm (δH) relative to Me4Si as an internal reference. J values are in Hz. 
 
 
Table 18. 13C NMR data for compound P5 
      
                                       P5                                       δC 
C-1 160.8 
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C-2 99.5 
C-3 161.61 
C-4 100.1 
C-4a 154.5 
C-5 148.5 
C-6 115.6 
C-7 123.5 
C-8 116.7 
C-8a 121.5 
C-9 180.8 
C-9a 103.6 
C-10a 146.3 
OCH3 56.5 
C-4’ (dihydropyran) 16.2 
C-5’ (dihydropyran) 31.8 
C-6’ (dihydropyran) 76.3 
C-7a’ and C-7b’ (dihydropyran) 26.7 
¥ Values in ppm (δC).  
 
In the 1H NMR spectra of P4 and P5 the group OCH3 was confirmed by the existence of a 
singlet due to three protons at 4.01 and 4.02 ppm, respectively. The signal for the protons of 
hydroxyl group appeared as a singlet (δH 13.20 and 12.61 ppm, respectively). 
The multiplicity and coupling constants for the protons observed in the 1H NMR spectra of 
P4 and P5 showed four signals corresponding to aromatic protons, namely H-4 or H-2 
respectively, and H-6, H-7, H-8 (values of δH between 6.46 and 7.81 ppm (P4); 6.26 and 7.82 ppm 
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(P5)). The presence of a fused dihydropyran ring was confirmed by the existence of two triplets 
due to two methylene protons (H-4’ and H-5’: δH 2.74 and 1.85 ppm (P4); 2.93 and 1.89 ppm (P5)) 
and the signal for the protons of two methyl groups appearing as a singlet (δH 1.38 ppm (P4); 1.39 
(P5)). 
The 13C NMR spectrum of P4 and P5 revealed signals that correspond to the carbon atom 
of the carbonyl group (δC 180.8 ppm) and to two aromatic rings (values of δC between 95.4 and 
161.9 ppm (P4); 99.5 and 161.6 ppm (P5)). The signal for the carbon of OCH3 group appeared at δC 
56.4 and 56.5 ppm, respectively. The spectrum revealed signals of the five carbons of the prenyl 
group present in these compounds. 
 
 
 
• NMR – 2D 
 
The position of the substituents on the xanthone skeleton was determined on the basis of 
HSQC and HMBC spectral analysis (Figures 27 and 28). 
 
In HMBC spectra of all prenylated xanthones, the hydrogen-bonded hydroxyl group (OH-
1) correlated with C-1, C-2 and C-9a, allowing the assignment of these carbon resonances. The H-
1´ of prenyl group in compound P1 and H-1´ and H-1´´ of prenyl group in compound P2, correlated 
with C-3 of xanthone ring indicating that all the prenylated xanthones had a 3,3-dimethylallyloxy 
group at C-3. For the diprenylated xanthones P2 and P3 it was also observed that the H-1´´ of the 
prenyl group correlated with C-4 and C-4a. 
In the case of dihydropyranoxanthones, it was observed that the H-4´ of the pyran ring of 
compounds P3 and P4 correlated with C-1, C-2, C-3, C-5´, and C-6´ indicating the presence of a 
2,3-dihydropyran ring. The H-4´ of the pyran ring of compound P5 correlated with C-3, C-4, C-4a, 
C-5´, and C-6´ indicating the presence of a 3,4-dihydropyran ring.  
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Figure 27. Main connectivities found in HMBC of prenylated xanthone P1-P5 
 
 
 
  
Figure 28. (a) Example of HSQC spectrum of prenylated xanthone P1 
(a) 
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Figure 28. (b) Example of HMBC spectrum of prenylated xanthone P1 
 
 
  
(b) 
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3. BIOLOGICAL ASSAYS 
 
In CEQUIMED-UP, a research area in increasing development has been the investigation of 
xanthones as potential antitumor agents. In this context, the synthesized compounds X1, X2, P1, 
P2, P3, P4 and P5 were evaluated by their effect on the in vitro growth of three human tumor cell 
lines, MCF-7 (breast adenocarcinoma), NCI-H460 (non-small cell lung cancer) and A375-C5 
(malignant melanoma). 
In table 19, the results of the evaluated activity are presented. 
 
 
Table 19. Effects of the synthesized compounds on the growth of human tumor cell lines 
 
Xanthone 
GI50 (µM) 
MCF-7 NCI-H460 A375-C5 
X1 >110 >90 N.R. 
X2 >150 >150 >150 
P1 >112.5 >112.5 >112.5 
P2 >12.4 >12.4 >12.4 
P3 >7.5 >12.4 >12.4 
P4 >150 >150 >150 
P5 >37.5 >37.5 >37.5 
 
Results expressed as GI50, concentration of compound that cause 50% inhibition of tumor cell lines growth, 
are means ± SEM (standard error of the mean) of 3 independent experiments performed in duplicate. 
Doxorubicin was used as positive control, GI50: MCF-7 = 0,065 ± 0,0085 µM; NCI-H460: 0,064 ± 0,0068 µM; 
A375-C5: 0,145 ± 0,0098 µM. NR, not reproducible. Final concentrations of DMSO (≤0,75%) did not interfere 
with the biological activity tested. 
 
In this essay, prepared in the laboratory according to the established in National Cancer 
Institute (NCI) (Monks, A. et al., 1991; Vichai, V. and Kirtikara, K., 2006), the compounds were 
tested in several concentrations until a maximum of 150 µM. The reasons why tests are not 
executed with superior concentrations are the following: i) the vehicle of compounds (dimethyl 
sulfoxide, DMSO) becomes toxic to the cells and ii) components with GI50 values above 150 µM, in 
principle, do not have a therapeutical interest. In fact, the majority of compounds with 
therapeutical interest present GI50 values in the scale of nanomolar. So that the compounds can 
be tested until a maximum concentration of 150 µM, without achieving the toxicity limit of DMSO, 
61 
 
they should be dissolved in a stock concentration of 60 mM. When such is not possible, they can 
only be tested in concentrations that do not hit the toxicity limit of DMSO and therefore not in all 
the desired concentrations. By analyzing table 19, none of the components hit the GI50 in the 
tested concentrations. 
The compounds X2 and P4 present concentrations of GI50 superior to 150µM, indicating 
that they are components that do not achieve the GI50 in the tested concentrations for this essay, 
in the three used cellular lines. Regarding the compounds X1 and P1, even though they have not 
been tested until the maximum desired concentration (150 µM), they were tested until 
concentrations close to 100 µM, not being able to achieve the GI50. Therefore, xanthones X1, X2, 
P1 and P4 are not active, showing results for GI50 above 100 µM. 
  
The evaluation of the other compounds (P2, P3 and P5) was limited by problems 
associated with their solubility; it was not possible to prepare stocks with the desired 
concentrations (60 mM) to test and determine the concentration value able to hit the GI50. It was 
only possible to determine a low limit of concentration until which the GI50 was not achieved. 
Therefore, we cannot conclude regarding the activity of P2, P3 or P5. 
 
It is also important to mention that the component X1 has not showed reproducible 
results. Even though it was possible to determine an amount of concentration of GI50 in the first 
two essays (medium value 45 µM), when new essays were executed the result has not been 
reproducible. This lack of reproducibility could be explained by the lack of stability of the 
compound that can have suffered alteration during the evaluation. 
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IV. EXPERIMENTAL PART  
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IV. EXPERIMENTAL PART 
 
GENERAL METHODS 
 
Purifications of compounds were performed by flash chromatography using Merck silica 
gel 60 (0.040-0.063 mm), chromatography flash cartridge (GraceResolv, Grace Company, 
Deerfield, IL, USA) and preparative thin layer chromatography (TLC) using Merck silica gel 60 
(GF254) plates. TLC was used for monitoring reactions.  
MW reactions were performed using glassware setup for atmospheric-pressure reactions 
and also 12mL or 50mL closed glass reactors (internal reaction temperature measurement with a 
fiber-optic probe sensor) and were carried out using an Ethos MicroSYNTH 1600 Microwave 
Labstation from Millestone (ThermoUnicam, Portugal). 
Melting points were obtained in a KÖfler microscope and are uncorrected. IR spectra were 
measured on an ATI Mattson Genesis series FTIR (software: WinFirst v.2.10) spectrophotometer in 
KBr microplates (cm-1). 1H and 13C NMR spectra were taken in DMSO-d6 or CDCl3 at room 
temperature, on Bruker Avance 300 (300.13 MHz for 1H and 75.47 MHz for 13C) or Bruker DRX-500 
(500.13 and/or 300.13 MHz for 1H and 125.77 and/or 75.47 MHz for 13C) spectrometers. Chemical 
shifts are expressed in δ (ppm) values relative to tetramethylsilane (Me4Si) as an internal 
reference and assignment abbreviations are the following: singlet (s), doublet (d), triplet (t) and 
doublet of doublets (dd). 13C NMR assignments were made by 2D HSQC and HMBC experiments 
(long-range C, H coupling constants were optimized to 7 and 1 Hz). 
HRMS spectra were recorded as electronic impact (EI) mode on a VG Autospec M 
spectrometer (m/z) at C.A.C.T.I. (Vigo, Spain). 
2-hydroxy-3-methoxybenzoic acid, phloroglucinol (1,3,5-trihydroxybenzene), prenyl 
bromide 95% and montmorillonite K10 clay were purchased from Sigma-Aldrich and were grade 
pro analysis.  
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Part I - Synthesis of 1,3-dihydroxy-5-methoxyxanthone (X1) 
 
 
A) General procedure for the synthesis of 1,3-dihydroxy-5-methoxyxanthone (X1) through 
Grover, Shah and Shah (GSS) classical method 
A mixture of phloroglucinol (1.2 g, 9.6 mmol), 2-hydroxy-3-methoxybenzoic acid (1.25 g, 
7.4 mmol) anhydrous zinc chloride (3 g), and phosphoryl chloride (12 mL) were heated, under 
stirring, at 70°C for 4h30. The deep-red reaction mixture obtained was poured onto crushed ice. 
The resulting red brownish solid was filtered, washed with water and dried. The crude product 
was then purified by flash chromatography (SiO2; a gradient of CHCl3/Me2CO, starting with 95:5). 
The product was crystallized from methanol to afford yellow crystals of xanthone. Compound 1,3-
dihydroxy-5-methoxyxanthone (X1) (39% yield) was identified by their spectroscopic and 
analytical data. 
 
 
 
B) General procedure for the synthesis of 1,3-dihydroxy-5-methoxyxanthone (X1) through 
modified GSS applying Eaton’s reagent 
To obtain Eaton’s reagent, a mixture of phosphorus pentoxide (6.5 g) and 
methanesulfonic acid (40 mL) was heated at 100°C for 30 min, under stirring, until a clear solution 
was obtained. Phloroglucinol (2,0 g, 16 mmol) and 2-hydroxy-3-methoxybenzoic acid (1.61 g, 9.6 
mmol) were added to this mixture and heating continued for 1h. The reaction mixture was poured 
into ice-water. The resulting solid was collected by filtration, washed with water and dried. The 
crude product was then purified by flash chromatography (SiO2; a gradient of CHCl3/Me2CO with 
crescent polarity). The products were crystallized from methanol to afford yellow crystals of both 
xanthones (X1 and X2). 
The compounds 1,3-dihydroxy-5-methoxyxanthone (X1) (23% yield) and 1-hydroxy-3-
mesyl-5-methoxyxanthone (X2) (15% yield) were identified by their spectroscopic and analytical 
data. 
 
 
 
 
65 
 
1,3-dihydroxy-5-methoxyxanthone (X1) - mp 219-222°C (methanol); IR (KBr) νmax: 3465, 3093, 
2936, 1654, 1605, 1567, 1499, 1450, 1362, 1176, 1107, 992 cm-1; 1H-NMR (300.13 MHz; DMSO-
d6): δ = 12.82 (1H, s, O-H1), 7.66 (1H, dd, J = 8.0 and 1.4 Hz, H-8), 7.50 (1H, dd, J = 8.0 and 1.4 Hz, 
H-6), 7.38 (1H, t, J = 8.0, H-7), 6.41 (1H, d, J = 2.1, H-4), 6.22 (1H, d, J = 2.1, H-2), 3.97 (3H, s, OCH3) 
ppm; 13C-NMR (75.47 MHz; DMSO-d6): δ = 179.8 (C-9), 166.1 (C-3), 162.8 (C-1), 157.2 (C-4a), 
147.9 (C-5), 145.4 (C-10a), 124.1 (C-7), 120.6 (C-8a), 116.7 (C-6), 115.7 (C-8), 102.1 (C-9a), 98.3 (C-
2), 94.2 (C-4), 56.2 (OCH3) ppm. EI-MS m⁄z (%): 259 (18), 258 (100) [M]
+, 244 (10), 243 (62), 229 
(5), 215 (6), 187 (26). EI-HRMS m⁄z  calc  for C14H10O5 : 258.0528, found: 258.0530. 
 
 
 
 
1-hydroxy-3-mesyl-5-methoxyxanthone (X2) - mp 201-204°C (methanol); IR (KBr) νmax: 3437, 
3086, 2937, 1651, 1618, 1581, 1495, 1439, 1363, 1283, 1184, 1111, 973 cm-1; 1H-NMR (300.13 
MHz; DMSO-d6): δ = 12.79 (1H, s, O-H1), 7.71 (1H, dd, J = 8.0 and 1.5 Hz, H-8), 7.58 (1H, dd, J = 8.0 
and 1.5 Hz, H-6), 7.45 (1H, t, J = 8.0, H-7), 7.18 (1H, d, J = 2.1, H-4), 6.83 (1H, d, J = 2.1, H-2), 3.99 
(3H, s, OCH3), 3.53 (3H, s, OSO2CH3) ppm; 
13C-NMR (75.47 MHz; DMSO-d6): δ = 181.1 (C-9), 162.2 
(C-1), 156.2 (C-4a), 154.8 (C-3), 148.1 (C-5), 145.7 (C-10a), 124.8 (C-7), 120.6 (C-8a), 117.5 (C-6), 
115.8 (C-8), 107.3 (C-9a), 104.6 (C-2), 101.6 (C-4), 56.4 (OCH3), 37.9 (OSO2CH3) ppm. EI-MS m⁄z 
(%): 337 (12), 336 (85) [M]+ , 258 (100), 243 (43), 229 (71), 187 (17), 97 (25), 83 (22), 69 (31). EI-
HRMS m⁄z  calc  for C15H12O7S : 336.0304, found: 336.0305. 
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Part II - Synthesis of prenylated xanthones (P1-P5) under MW irradiation 
 
 
A) General procedure for the synthesis of prenylated xanthones (P1 and P2) under MW 
irradiation in alkaline medium 
A mixture of 1,3-dihydroxy-5-methoxyxanthone (X1) (2 mmol), prenyl bromide (4 mmol), 
Cs2CO3 (4 mmol) in dry acetone (200 mL), in a two-necked glassware apparatus, provided with 
magnetic stirring bar, fiber-optic temperature control and reflux condenser, was heated for 1h 
according to the following microwave program: Power:200W; temperature: 62°C; ramp time: 5 
min; hold time: 55 min; final temperature 59°C. After cooling, the mixture was filtered and 
washed with acetone. The solvent was removed under reduced pressure and the collected crude 
product was purified by flash chromatography (SiO2; a gradient of hexane/ethyl acetate, with 
crescent polarity). The isolation of the components of the mixture was then carried out by 
preparative TLC (SiO2; hexane/ethyl acetate 75:25). Prenylated xanthones P1 and P2 were 
crystallized from CH2Cl2/petroleum ether (60-80) to afford yellow crystals. These two compounds 
were shown to possess spectroscopic and analytical data as next described. Compounds yields 
were 15% for P1 and 5% for P2. 
 
 
 
B) General procedure for the synthesis of prenylated xanthones (P3 - P5) under MW 
irradiation with Montmorillonite K10 clay 
A slurry of the K10 clay (20 equiv by weight, 10 g) in CHCl3 (30mL) was treated with the 
1,3-dihydroxy-5-methoxyxanthone (X1) (2 mmol), followed by the addition of prenyl bromide (4 
mmol) in a 100mL closed microwave reactor, provided with magnetic stirring bar and fiber-optic 
temperature control. The mixture was irradiated at 180W for 45 min (ramp time: 5 min; hold 
time: 40 min) and the final temperature was 96°C. After cooling, the reaction mixture was filtered 
under vacuum, washed with CH2Cl2, Me2CO and MeOH, and the solvent evaporated under 
reduced pressure. The recovered clay was reactivated by washing with MeOH. The crude product 
was purified by flash chromatography (SiO2; hexane/ethyl acetate 95:5) and the isolation of the 
components of the mixture was then carried out by preparative TLC (SiO2; hexane/ethyl acetate 
6:4). Prenylated xanthones were then crystallized from n-hexane/ethyl acetate to obtain yellow 
crystals. The prenylated xanthones P3, P4 and P5 were identified by their spectroscopic and 
analytical data as next described. Compounds yields were 0,3% for P3, 3% for P4 and 13% for P5. 
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1-hydroxy-5-methoxy-3-(3-methylbut-2-enyloxy)xanthone (P1) – mp 158-160°C 
(CH2Cl2/petroleum ether (60-80)); IR (KBr) νmax: 3427, 2965, 2914, 2843, 1650, 1614, 1570, 1488, 
1431, 1283, 1153, 1094, 955 cm-1; 1H-NMR (300.13 MHz; CDCl3): δ = 12.81 (1H, s, O-H1), 7.81 (1H, 
dd, J = 8.0 and 1.7 Hz, H-8), 7.29 (1H, t, J = 8.0, H-7), 7.22 (1H, dd, J = 8.0 and 1.7 Hz, H-6), 6.54 
(1H, d, J = 2.3, H-4), 6.36 (1H, d, J = 2.3, H-2), 5.50 (1H, t, J = 6.7, H-2’), 4.59 (2H, d, J = 6.7, H-1’), 
4.03 (3H, s, OCH3), 1.82 and 1.76 (3H, s, H-4a’ and H-4b’) ppm; 
13C-NMR (75.47 MHz; CDCl3): δ = 
180.7 (C-9), 166.1 (C-3), 163.2 (C-1), 157.5 (C-4a), 148.2 (C-5), 146.3 (C-10a), 139.3 (C-3’), 123.5 (C-
7), 121.5 (C-8a), 118.5 (C-2’), 116.7 (C-8), 115.6 (C-6), 103.8 (C-9a), 98.2 (C-2), 93.3 (C-4), 65.5 (C-
1’), 56.4 (OCH3), 25.8 and 18.3 (C-4a’ and C-4b’) ppm. EI-MS m⁄z (%): 326 (6) [M]
+, 309 (11), 259 
(9) , 258 (100), 243 (25), 187 (9). EI-HRMS m⁄z  calc  for  C19H18O5 : 326.1154, found: 326.1157. 
 
  
 
1-hydroxy-5-methoxy-4-(3-methylbut-2-enyl)-3-(3-methylbut-2-enyloxy)xanthone (P2) – mp 
116-118°C (CH2Cl2/petroleum ether (60-80)); IR (KBr) νmax: 3447, 2956, 2920, 2849, 1648, 1610, 
1579, 1493, 1439, 1273, 1170, 1096, 963 cm-1; 1H-NMR (300.13 MHz; CDCl3): δ = 12.96 (1H, s, O-
H1), 7.79 (1H, dd, J = 7.9 and 1.8 Hz, H-8), 7.27 (1H, t, J = 7.9, H-7), 7.21 (1H, dd, J = 7.9 and 1.8 Hz, 
H-6), 6.39 (1H, s, H-2), 5.50 (1H, t, J = 6.6, H-2’), 5.30 (1H, t, J = 7.4, H-2”), 4.63 (2H, d, J = 6.6, H-1’), 
3.99 (3H, s, OCH3), 3.55 (2H, d, J = 7.4, H-1”), 1.87 and 1.67 (3H, s, H-4a” and H-4b”), 1.81 and 1.76 
(3H, s, H-4b’ and H-4a’) ppm; 13C-NMR (75.47 MHz; CDCl3): δ = 181.3 (C-9), 163.7 (C-3), 161.7 (C-
1), 153.8 (C-4a), 148.7 (C-5), 146.7 (C-10a), 138.5 (C-3’), 131.7 (C-3”), 123.2 (C-7), 122.2 (C-2”), 
121.2 (C-8a), 119.0 (C-2’), 116.5 (C-8), 115.6 (C-6), 108.4 (C-4), 103.4 (C-9a), 95.2 (C-2), 65.7 (C-1’), 
56.2 (OCH3), 25.9 and 17.6 (C-4b” and C-4a”), 25.8 and 18.3 (C-4b’ and C-4a’), 21.8 (C-1”) ppm. EI-
MS m⁄z (%): 394 (6) [M]+, 377 (17), 326 (21), 322 (17), 311 (45), 309 (100), 294 (26), 271 (17), 258 
(17). EI-HRMS m⁄z  calc  for C24H26O5 
 : 394.1780, found: 394.1769. 
 
 
 
1-hydroxy-5-methoxy-4-(3-methylbut-2-enyl)-6’,6’-dimethyl-4’,5’-dihydropyran(2’,3’:3,2) 
xanthone (P3) – mp >300°C (decomp.); IR (KBr) νmax: 3429, 2954, 2927, 2872, 1651, 1613, 1579, 
1495, 1441, 1271, 1165, 1102, 803 cm-1; 1H-NMR (300.13 MHz; CDCl3): δ = 13.10 (1H, s, O-H1), 
7.81 (1H, dd, J = 7.8 and 1.8 Hz, H-8), 7.30 (1H, t, J = 7.8, H-7), 7.22 (1H, dd, J = 7.8 and 1.8 Hz, H-
6), 6.26 (1H, t, J = 7.4, H-2”), 4.01 (3H, s, OCH3), 3.98 (2H, d, J = 7.4, H-1”), 2.17 (2H, t, J = 6.8, H-4’), 
2.01 (2H, t, J = 6.8, H-5’), 1.75 (6H, s, H-4a” and H-4b”), 1.38 (6H, s, H-7a’ and H-7b’) ppm; 13C-
NMR (75.47 MHz; CDCl3): δ = 180.8 (C-9), 164.2 (C-3), 163.6 (C-1), 152.7 (C-4a), 148.4 (C-5), 146.1 
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(C-10a), 135.4 (C-3”), 123.4 (C-7), 121.4 (C-8a), 116.7 (C-8), 115.8 (C-6), 108.1 (C-4), 103.4 (C-9a), 
95.1 (C-2), 94.3 (C-2”), 76.7 (C-6’), 56.6 (OCH3), 31.6 (C-5’), 28.6 (C-1”), 26.2 (C-7a’ and C-7b’), 18.9 
(C-4a” and C-4b”), 15.9 (C-4´) ppm. 
 
 
 
1-hydroxy-5-methoxy-6’,6’-dimethyl-4’,5’-dihydropyran(2’,3’:3,2)xanthone (P4) – mp 154-156°C 
(n-hexane/ethyl acetate); IR (KBr) νmax: 3445, 2954, 2927, 2841, 1650, 1617, 1576, 1493, 1445, 
1269, 1156, 1098, 992 cm-1; 1H-NMR (300.13 MHz; CDCl3): δ = 13.20 (1H, s, O-H1), 7.81 (1H, dd, J = 
8.0 and 1.8 Hz, H-8), 7.27 (1H, t, J = 8.0, H-7), 7.21 (1H, dd, J = 8.0 and 1.8 Hz, H-6), 6.46 (1H, s, H-
4), 4.01 (3H, s, OCH3), 2.74 (2H, t, J = 6.8, H-4’), 1.85 (2H, t, J = 6.8, H-5’), 1.38 (6H, s, H-7a’ and H-
7b’) ppm; 13C-NMR (75.47 MHz; CDCl3): δ = 180.8 (C-9), 161.9 (C-3), 160.4 (C-1), 155.3 (C-4a), 
148.2 (C-5), 146.4 (C-10a), 123.1 (C-7), 121.4 (C-8a), 116.7 (C-8), 115.5 (C-6), 104.2 (C-2), 102.8 (C-
9a), 95.4 (C-4), 76.3 (C-6´), 56.4 (OCH3), 31.7 (C-5´), 26.7 (C-7a´ and C-7b´), 16.0 (C-4´) ppm. EI-MS 
m⁄z (%): 327 (7), 326 (41) [M]+, 311 (10), 309 (33), 283 (21), 271 (100), 270 (21), 258 (5), 256 (9), 
242 (11). EI-HRMS m⁄z calc for C19H18O5 : 326.1154, found: 326.1153. 
 
 
 
1-hydroxy-5-methoxy-6’,6’-dimethyl-4’,5’-dihydropyran(2’,3’:3,4)xanthone (P5) – mp 215-217°C 
(n-hexane/ethyl acetate); IR (KBr) νmax: 3424, 2967, 2933, 2851, 1657, 1612, 1577, 1492, 1432, 
1268, 1158, 1099, 968 cm-1; 1H-NMR (300.13 MHz; CDCl3): δ= 12.61 (1H, s, O-H1), 7.82 (1H, dd, J = 
7.9 and 1.7 Hz, H-8), 7.29 (1H, t, J = 8.0, H-7), 7.22 (1H, dd, J = 7.9 and 1.7 Hz, H-6), 6.26 (1H, s, H-
2), 4.02 (3H, s, OCH3), 2.93 (2H, t, J = 6.8, H-4’), 1.89 (2H, t, J = 6.8, H-5’), 1.39 (6H, s, H-7a’ and H-
7b’) ppm; 13C-NMR (75.47 MHz; CDCl3): δ = 180.8 (C-9), 161.6 (C-3), 160.8 (C-1), 154.5 (C-4a), 
148.5 (C-5), 146.3 (C-10a), 123.5 (C-7), 121.5 (C-8a), 116.7 (C-8), 115.6 (C-6), 103.6 (C-9a), 100.1 
(C-4), 99.5 (C-2), 76.3 (C-6´), 56.5 (OCH3), 31.8 (C-5´), 26.7 (C-7a´ and C-7b´), 16.2 (C-4´) ppm. EI-
MS m⁄z (%): 327 (10), 326 (48) [M]+, 311 (30), 309 (9), 272 (13), 271 (100), 270 (9), 258 (13), 256 
(14), 242 (20). EI-HRMS m⁄z calc for C19H18O5 : 326.1154, found: 326.1157. 
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Part III – Tumor Cell Growth Assay 
 
 
Stock solutions of compounds were prepared in DMSO (Sigma Chemical Co.) and stored at 
4°C. The samples were freshly diluted with culture medium just prior to the assays.  
 
TUMOR CELL GROWTH ASSAY: The effect of compounds on the growth of the human tumor cell 
lines was evaluated according to the procedure adopted by the National Cancer Institute (NCI, 
USA) in the in vitro anticancer drug discovery screen. This assay is based in the protein-binding 
dye sulforhodamine B (SRB) to indirectly assess cell growth (Monks, A. et al., 1991; Vichai, V. and 
Kirtikara, K., 2006). The following human tumor cell lines were used:  MCF-7 (breast 
adenocarcinoma), NCI-H460 (non-small cell lung cancer) and A375-C5 (malignant melanoma). 
Cells were routinely cultured in RPMI-1640 medium with ultraglutamine 1 (Lonza) supplemented 
with 5% heat-inactivated fetal bovine serum (FBS, PAA Laboratories), at 37°C in an humidified 
atmosphere containing 5% CO2. For the SRB assay experiments, cells were plated in 96-well plates 
at the following densities: at 5000 cells/well for MCF7 and NCI-H460 cell lines and at 7500 
cells/well for A375-C5. The cell density for each cell line was chosen  based on previous studies 
(Neves, M.P. et al., 2012 and 2011) in order to ensure cellular exponential growth throughout all 
the experimental period, ,. Cells were further incubated and allowed to adhere for 24 h and then 
treated with five serial dilutions of studied compounds (prepared in culture medium) for 48 h.  In 
addition, cells were also treated with five serial dilutions of doxorubicin (Sigma Aldrich), as a 
positive control, and with the vehicle of the compounds, DMSO (at maximum concentration of 
used). Following this incubation period, cells were fixed in situ with 10% of trichloroacteic acid 
(TCA, Merck), washed with water, and incubated with SRB (Sigma Aldrich) for 30 minutes. After 
washing with 1% acetic acid (Merck), the bound dye was solubilized with 10 mM Tris-BASE (Sigma 
Aldrich) and the absorbance was measured at 510 nm in a microplate reader (Synergy Mx, 
Biotek). A dose–response curve was generated and GI50, corresponding to the concentration of 
compound that inhibits 50% of the net cell growth, was determined as previously described 
(Monks, A. et al., 1991). 
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V. CONCLUSIONS 
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CONCLUSIONS 
 
 Despite all the advances that science has had over the years, Nature remains today the 
larger source of new drugs. 
 Recently there has been an increased interest in xanthones, due to their diverse 
pharmacological activities and to their capacity of binding to different classes of receptors, which 
make them “privileged structures” in Medicinal Chemistry. Therefore, xanthones obtained by 
synthesis began to represent a significant part of the derivatives described in literature. 
  
 
 In this work, seven new compounds were obtained – X1, X2, P1, P2, P3, P4 and P5 - by 
the application of different methodologies and reaction conditions. 
The synthesis of 1,3-dihydroxy-5-methoxyxanthone (X1) by GSS was a successful way to 
obtain X1 in moderate yields (39%). When the GSS reaction was modified by the use of Eaton’s 
reagent as condensation agent, another product X2 was obtained in 15% yield and the yield of X1 
was lower (23%). 
 To obtained prenylated xanthones from X1, the synthetic approach used involved 
MAOS. The reaction was not very selective and different products were obtained. In an alkaline 
medium (Cs2CO3), four products were originated, but only two were in sufficient quantity to be 
isolated and identified – the prenylated xanthones 1-hydroxy-5-methoxy-3-(3-methylbut-2-
enyloxy)xanthone (P1) and 1-hydroxy-5-methoxy-4-(3-methylbut-2-enyl)-3-(3-methylbut-2-
enyloxy)xanthone (P2), obtained in 15% and 5% yield, respectively. 
MAOS was also combined with heterogeneous catalysis, using montmorillonite K10 clay 
as catalyst being obtained three main products: 1-hydroxy-5-methoxy-4-(3-methylbut-2-enyl)-
6’,6’-dimethyl-4’,5’-dihydropyran(2’,3’:3,2)xanthone (P3, 0,3% yield), 1-hydroxy-5-methoxy-6’,6’-
dimethyl-4’,5’-dihydropyran(2’,3’:3,2)xanthone(P4, 3% yield), 1-hydroxy-5-methoxy-6’,6’-
dimethyl-4’,5’-dihydropyran(2’,3’:3,4)xanthone (P5, 13% yield). 
 All the compounds were structurally elucidated using analytical techniques like IR, NMR 
and HRMS, and evaluated by their antitumor activity in human tumor cell lines.  
According to the data (GI50), the compounds xanthones X1, X2, P1 and P4 were not 
active, showing results for GI50 above 100 µM. Concerning the compounds P2, P3 and P5, because 
it was only possible to determine a low limit of concentration until which the GI50 was not 
achieved, it was not possible to conclude regarding the activity of P2, P3 or P5.  
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In the future, once the solubility of the compounds was a limiting factor of this 
evaluation, it must be improved to enable the preparation of solution in higher concentrations 
(60mM) that allow the determination of IG50. For a future and more conclusive evaluation, the 
solubility can be improved by using co-solvents like Tweens, or even by the incorporation of the 
compounds in macromolecules like cyclodextrins (Castro, C.A., et al., 1995).  
 
Therefore, according to the aims mentioned before, the work developed enabled to: 
• obtain the building block 1,3-dihydroxy-5-methoxyxanthone;  
•  apply different methodologies of synthesis resulting in five new prenylated 
xanthone derivatives – cyclic and open-chain;   
• structurally elucidate the new compounds using analytical techniques; 
• evaluate their antitumor activity. 
 
 
The xanthone scaffold revealed to be promising to the development of new biological 
active compounds. In the future it will be important to optimize the experimental conditions for 
MAOS and heterogeneous catalysis, once they can be methodologies of election in the synthesis 
of xanthone derivatives. 
 
  
Xanthones comprise an ever growing and considerably diverse group of compounds in 
terms of structure, occurrence, and bioactivity. They represent attractive targets for both total 
synthesis and associated exploration of analogues for the purpose of exploiting the infinity of 
diverse and specific bioactivities that this class of compounds possesses. 
The synthesis of the xanthone derivatives is an exciting contemporary area of chemical 
research, and the work developed shows that the evolution of chemical synthesis, through the 
application of new “non-classical” methodologies, can be a powerful tool to create structural 
diversity, leading to new and improved bioactive compounds of great interest.  
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ATTTACHMENT  I : COMPOUNDS STRUCTURES 
NAME STRUCTURE ABBREVIATION 
 
1,3-dihydroxy-5-methoxyxanthone 
 
 
X1 
 
1-hydroxy-3-mesyloxy-5-methoxyxanthone 
 
 
X2 
 
1-hydroxy-5-methoxy-3-(3-methylbut-2-
enyloxy)xanthone 
 
 
 
P1 
 
1-hydroxy-5-methoxy-4-(3-methylbut-2-enyl)-
3-(3-methylbut-2-enyloxy)xanthone 
O
O OH
O
OCH3
 
 
 
P2 
 
1-hydroxy-5-methoxy-4-(3-methylbut-2-enyl)-
6’,6’-dimethyl-4’,5’-
dihydropyran(2’,3’:3,2)xanthone 
 
 
 
P3 
 
1-hydroxy-5-methoxy-6’,6’-dimethyl-4’,5’-
dihydropyran(2’,3’:3,2)xanthone 
 
 
P4 
 
1-hydroxy-5-methoxy-6’,6’-dimethyl-4’,5’-
dihydropyran(2’,3’:3,4)xanthone 
 
 
 
P5 
 

